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Dissolution testing is one of the primary methods employed not only as a quality control 
tool but also to evaluate bioequivalence and assess the effect of process and formulation parameters 
on drug release. Currently, there is no compendial-level method to assess dissolution of particulate 
systems administered in the periodontal pocket. Therefore, the goal of this work is to develop and 
demonstrate the utility of dissolution methods for microparticles applied in the periodontal pocket. 
Arestin®, a clinically used extended release periodontal system was used as the reference product. 
It is composed of poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with an antibacterial 
drug, minocycline hydrochloride (MIN). Two methods were evaluated in this study. The first 
method utilized a standard USP IV apparatus modified to include a dialysis tube with dispersed 
microparticles, which was developed as a rapid screening method.  In the second method, a novel 
apparatus was designed by our group to simulate the in vivo environment of the periodontal pocket. 
The applicability of these methods was evaluated by rigorously testing for reproducibility and 
discriminatory ability. To test the discriminatory ability of the developed methods, a panel of MIN-
loaded PLGA microparticles that differed in composition and process conditions were utilized. 
The method utilizing the USP IV apparatus was equipped with online UV-analysis and was carried 
out at a flow rate of 10mL/min for 3 days. Microparticles that showed different dissolution profiles 
in this method were tested in the novel, more biorelevant small volume apparatus, which was 
designed to hold 250µL of gingival crevicular fluid simulant (sGCF), where the particles are 
 v 
dispersed. sGCF was continuously delivered to the device at a biorelevant flow rate and collected 
daily for dug content analysis using a stability-indicating UPLC method. Both the developed 
methods could discriminate between Arestin® and the comparators. Release of MIN was largely 
dependent on molecular weight of PLGA used, with higher molecular weight showing higher 
release. The methods evaluated in this work can be used in routine quality control analysis to detect 
batch-to-batch variability. Future studies can evaluate the applicability of the developed methods 
to assess bioequivalence of MIN-loaded periodontal systems. 
 vi 
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1.0 Introduction 
Dissolution is the process by which a solute in a solid, liquid or gaseous state dissolves in 
a solvent, yielding a solution [1]. In the pharmaceutical context, dissolution is the process by which 
the drug in a drug product dissolves in body fluids and becomes available for absorption. There 
are a variety of factors that affect the rate and extent of dissolution. Dissolution testing is a pivotal 
quality control test that assesses the impact of formulation and process variables on the drug 
product. In addition, dissolution testing has implications for better design of drug products and 
prediction of in vivo performance. This chapter discusses the concept of dissolution testing, 
followed by the applications of dissolution testing, development of dissolution methods and 
ultimately the currently used methods for dissolution testing of particulate systems. 
1.1 The Concept of Dissolution Testing 
The concept of dissolution testing was first explored at the end of the 19th century. 
However, the use of in vitro dissolution testing methods in the pharmaceutical industry gained 
importance only in the mid-20th century [2]. Since then, dissolution testing has experienced a 
phenomenal increase in importance and is currently one of the most important characterization 
tests employed in the pharmaceutical industry. With around 84 % of the top 50 drug products in 
the US and European markets administered orally [3], dissolution testing methods for tablets and 
capsules are understandably the most advanced. However, with the advent of a vast number of 
novel drug delivery systems, development of dissolution testing methods for modified-release 
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dosage forms has gained increased recognition. Interest has concurrently developed in correlating 
in vitro dissolution data to in vivo product performance, creating the need for development of 
predictive in vitro dissolution tests.  
According to the International Union of Pure and Applied Chemistry (IUPAC), the rate of 
dissolution can be defined as the change in concentration of a dissolved substance over a certain 
period of time [4]. The concept of rate of dissolution was first introduced in 1897 by Arthur A. 
Noyes and Willis R. Whitney [5]. They studied the dissolution of two sparingly soluble salts in 
water and observed that the rate of dissolution of a compound is proportional to the difference 
between the instantaneous concentration of the solution and the saturation solubility. This 
observation, stated mathematically, forms the Noyes and Whitney equation (Equation 1). 
𝑑𝐶
𝑑𝑡
= 𝑘(𝐶s − 𝐶t)                                                                                                                     (1) 
Where,  
dC = change in concentration over time dt 
Ct  = concentration at time t 
Cs = saturation solubility of substance 
  k = constant 
Noyes and Whitney proposed the mechanism of dissolution to the formation of a thin layer 
of unstirred liquid forming around the particle. They called this the diffusion layer and particles 
were proposed to diffuse from the diffusion layer to the bulk fluid [5] . To quantify the diffusion 






                                                                                                                       (2) 
Where, 
dM = mass diffused in time dt 
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S = surface area 
D = diffusion coefficient 
dC = concentration difference 
dx = distance to overcome 
As reviewed by Dokoumetzidis, A. and Macheras, P., the next development in the field 
took place at the dawn of the 20th century. In 1900, Erich Brunner and Stanis-laus von Tolloczko 
proposed further conditions under which Equation 1 holds [2]. According to their paper, properties 
of the exposed surface, including surface area and structure, rate of agitation, temperature and 
arrangement of the apparatus influenced the rate of dissolution. They modified Equation 1 to 
include a term for exposed area (S) available for dissolution (Equation 3). 
𝑑𝐶
𝑑𝑡
= 𝑘1𝑆(𝐶S − 𝐶t)                                                                                                                   (3) 
In 1904, Erich Brunner and Nernst Walther combined the diffusion layer theory with Fick’s 






(𝐶s − 𝐶t)                                                                                                                   (4) 
Where, 
V = volume of dissolution media 
h = thickness of diffusion layer 
In the above equations, surface area is considered to be constant during the experiment. 
However, in most practical cases, the surface area of a particle reduces as it continues to dissolve 
in a liquid [6]. In 1931, A. W. Hixson and J. H. Crowell studied the dissolution of solids under 
perfect sink conditions [7]. Under sink conditions, the change in concentration of the bulk fluid is 
negligible and thus can be considered to be a constant. Incorporating these changes in Equation 2, 
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= −𝑘2𝑆t                                                                                                                         (5) 
Where, 
St = surface area of the particle at time t 
For a perfectly spherical particle, the surface area S is proportional to its mass, M2/3. 
Substituting surface area for mass in Equation 5 and integrating the resulting equation gives 





− 𝑘3𝑡                                                                                                             (6) 
Where, 
Mt = mass of substance at time t 
M0 = initial mass of substance 
This equation holds true for non-disintegrating, perfectly spherical particles undergoing 
dissolution under sink conditions. The Hixson-Crowell equation is one of the most commonly used 
equations to model drug release from pharmaceutical dosage forms. However, application of the 
equation becomes challenging as it is difficult to provide perfectly sink conditions and have non-
disintegrating dosage forms in a practical setting. Thus, various other models have been developed 
over the years in order to model different types of dosage forms. 
Although the concept of in vitro dissolution had advanced considerably in the first half of 
the 20th century, its applications were limited to the field of chemical engineering [2]. During this 
time, the in vivo availability of the drug was thought to be determined by the disintegration time 
of tablets [8]. However, a number of bioavailability concerns were raised in the 1950s. These 
incidences brought to light the insufficiency of disintegration to test the equivalence of two 
 5 
products [9-11]. The importance of in vitro dissolution testing as a quality control tool was 
recognized in 1970, when dissolution testing was adopted as a routine quality control test in 6 
monographs in the United States Pharmacopoeia (USP) and National Formulary (NF) [2].  
According to the USP, a dissolution test evaluates the rate and extent to which a compound 
(drug) forms a solution (dissolves) under a predetermined set of carefully controlled conditions 
[12]. There are multiple variables which need to be considered while developing a dissolution 
method. These are mentioned in the USP general chapter on development and validation of 
dissolution methods [13] and would be highlighted later in the document. As with any other 
analytical method, a dissolution method should be robust, reproducible and discriminatory in 
nature. However, with the increasing applications of in vitro dissolution testing, new paradigms 
are being set to define an ideal dissolution test. 
1.1.1  Characteristics of an Ideal Dissolution Test 
The ideal characteristics of a dissolution test vary according to their intended application. 
In general, dissolution tests are expected to be discriminatory in nature, robust and reproducible 
[14]. Dissolution tests intended to be used for predicting in vivo release should display certain level 
of correlation.    
1.1.1.1 Discriminatory Potential 
One of the core characteristics of a dissolution test is its discriminatory potential. A 
dissolution method should be able to differentiate between products that are not equivalent to one 
another. However, the method should not be so sensitive that it discriminates between products 
that are clinically equivalent [15]. The discriminatory potential of a dissolution method is 
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influenced by the type of apparatus, media composition, temperature and stir/flow rate. Of note, 
the criteria chosen to decide equivalence also determines the discriminatory potential of a method. 
For example, in Figure 1 the test is discriminatory when the one-point acceptance criteria states 
that more than 90 % of the drug should dissolve within 90 minutes. However, the same test is non-
discriminatory when the acceptance criteria states that more than 90 % of the drug should be 
dissolved at 120 minutes. 
 
Figure 1. Representative Figure Showing Dependence of Discriminatory Potential on Acceptance Criteria 
1.1.1.2 Robustness 
Robustness is the ability of the dissolution method to remain unaffected by small, 
deliberate changes made to the method [16]. Like any other analytical procedure, a dissolution test 
should be robust and not be sensitive to small changes in method parameters. There should not be 
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differences in results obtained by different labs or analysts. The dissolution method should not be 
sensitive to small changes in rate of agitation, media composition and temperature. [15]. 
1.1.1.3 Transferability/ Reproducibility 
The method should be simple enough to enable adoption by different laboratories [14]. The 
results should be independent of the source of materials, quality of solvent and brand of equipment. 
Anyone with the standard operation procedure (SOP) for the method should be able to run the test 
provided they have the required equipment at hand. Easy transferability of the test becomes 
important as it is likely that the same dissolution method would be used for routine quality control 
analysis in the future.   
1.1.1.4 Ability to Predict In-vivo Response 
In vitro dissolution tests are one of the major characterization methods used to simulate in 
vivo drug release. Ideally, there should be a strong correlation between a dissolution test and in 
vivo response (absorption/plasma drug concentration) of the drug product. Thus, an in vitro test 
could serve as a predictor of in vivo bioavailability [17]. Use of biorelevant media, reservoir 
volumes and agitation rates that mimic in vivo environments help in enhancing the predictive 
power of dissolution tests. As we will see further, a dissolution test which predicts in vivo response 
plays an important role in determining bioequivalence. The use of predictive dissolution testing in 
obtaining biowaivers increases its importance exponentially.  
 8 
1.1.2  Applications of Dissolution Testing 
Dissolution testing has evolved from being a routine quality control method to an important 
evaluation technique used in the pharmaceutical industry. Reliable dissolution tests find 
applications in various areas of the product life-cycle, from drug development and optimization to 
quality assurance post marketing, as described below.  
1.1.2.1 Product Development 
An important role of in vitro dissolution testing in the early stages of drug development is 
in product development. A good dissolution test can discriminate between products that are 
different due to differences in formulation and/or manufacturing conditions. Thus, dissolution 
testing is used to screen products prepared using different excipients and using different processing 
parameters. Drug products that show superior and reproducible dissolution profiles are further 
optimized to produce a marketable formulation [18]. The use of in vitro dissolution testing in 
product development has become more important as manufacturers are shifting to developing 
products using the quality by design (QbD) approach. For example, dissolution testing can provide 
information on the effect of process parameters on product performance. Such knowledge can be 
utilized to determine a design space, as explained by Dickinson, P. A. and colleagues [19].  Use 
of a design space reduces the regulatory burden on manufacturers and provides them some 
flexibility in modifying manufacturing conditions post approval.  
1.1.2.2 Routine Quality Control Analysis 
The most common use of a validated dissolution method is for ensuring batch-to-batch 
reproducibility. The Food and Drug Administration (FDA) requires dissolution testing to be 
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performed on all batches before they are released to the market. In case the produced batches fail 
to meet the acceptance criteria for dissolution, the batches will be rejected. Dissolution testing is 
also a required characterization test for assessing shelf-life stability of drug products [20]. If a 
stability sample fails in the dissolution test, the batch must be recalled from the market. 
1.1.2.3 Biowaiver Application for Drugs containing Lower Strength of Actives 
Another important application of dissolution testing is for the request of biowaivers. If a 
manufacturer has got an approval for a higher strength of dosage form, in vivo bioequivalence 
studies for lower strength products can be waived [21]. Such biowaivers are accepted if the relative 
ratios of API-to-excipients of the lower strength product and approved product are similar. Instead 
of single-point comparisons routinely used in the industry, biowaiver applications require 
dissolution profile comparisons. The dissolution profiles are compared at each timepoint for 
similarity and differences. If the difference factor (f1) between the two dissolution profiles is below 
15 (0 – 15) and the similarity factor (f2) is above 50 (50 – 100), the dissolution profiles are said to 
be similar and in vivo bioequivalence studies can be waived. The f1 and f2 values can be calculated 




] × 100                                                                                                       (7) 






 ×  100]                                               (8) 
Where,  
n = number of time points 
Rt = dissolution value of the reference at time t 
Tt = dissolution value of the test at time t 
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1.1.2.4 Scale-Up and Post Approval Changes 
The FDA allows for in vitro dissolution testing data to substitute for in vivo bioequivalence 
tests for most scale-up and post approval changes. Minor changes in excipient concentrations, 
changes in batch size or manufacturing unit can be approved based on similarity in dissolution 
profiles of the new and old products [22].  
1.1.2.5 Generic Product Bioequivalence 
In vivo bio-equivalence studies can be waived for most immediate-release (IR) 
formulations containing highly soluble and highly permeable APIs. Extended-release (ER) 
formulations usually require in vivo bioequivalence studies to be performed only on the highest 
strength. In vitro data is acceptable for the other strengths, provided that in vivo bioequivalence 
studies are performed on the highest strength of drug product [14]. However, biowaivers for 
generic drug products of low therapeutic index drugs are understandably not accepted. FDA also 
requires modified release (MR) dosage forms to be tested for alcohol effects. Different levels of 
ethanol are added to the dissolution media to see if burst release occurs from MR formulations. 
Burst release or “dose dumping” from MR formulations is unacceptable. If an in vitro-in vivo 
correlation has been established, in vitro dissolution testing can be substituted for in vivo 
bioequivalence studies for IR/ER formulations administered orally or non-orally, but these cases 
are dealt on a case basis. Thus, dissolution testing is the most important in vitro test to determine 
bioequivalence and in some cases bioavailability of drug products.  
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1.1.3  Role of Dissolution Testing in Assessing Bioavailability and Bioequivalence 
Bioavailability (BA) can be defined as the fraction of the drug from the dosage form that 
reaches the systemic circulation unchanged [23]. Comparative BA studies compare the 
bioavailabilities of two or more formulations of the same drug [24]. Consequently, drug products 
are said to be bioequivalent (BE) when there is no significant difference in their BAs. In order to 
be BE, the drug products need to be either pharmaceutical equivalents or pharmaceutical 
alternatives. Pharmaceutically equivalent drug products contain identical amounts of the same 
API. Pharmaceutical alternatives are drug products that contain the same API but it may be in a 
different dosage form, amount or chemical form. The various criteria to determine BE and the use 
of in vitro dissolution tests as surrogate to clinical studies to prove BE has been discussed in the 
following sections. 
1.1.3.1 Criteria for Bioequivalence 
The currently employed method for determining bioequivalence for two drug products is 
the 80/125 criteria after log transformation [25]. Accordingly, FDA considers two drug products 
to be bioequivalent if the 90 % confidence interval of the ratio of geometric means of key 
pharmacokinetic properties after log-transformation is within 80 % to 125 %. The key 
pharmacokinetic properties that are required to meet this criterion include the Cmax (maximum 
plasma concentration), area under the curve (AUC) from time 0-t and AUC from time 0-∞ [26]. 
Figure 2 illustrates the criteria required in order to prove BE. 
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Figure 2. Illustration of criteria required to prove bioequivalence (Adapted from [27]). In this figure, The green 
lines are examples of bioequivalent formulae and red lines are examples of bioinequivalent formulae. 
1.1.3.2 Tests for Determining Bioequivalence 
When BA and BE regulations were first introduced, there was confusion as to whether in 
vivo studies were required to be performed on drugs that were approved prior to introduction of 
these regulations. In 1974, the Drug Bioequivalence Study Panel which was a part of the Office of 
Technology Assessment stated that it was not practical to perform BE studies on all drugs or drug 
products that were approved before the inclusion of BA guidelines [28]. It was proposed that a 
certain group of drugs be identified where evidence of BA is crucial. In vivo studies should be 
required to determine BA and BE of only these drug products. These suggestions were 
incorporated in the guidelines in 1977 and in vivo efficacy studies were waived for some drugs 
that were approved before 1962 [29]. 
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The current tests that can be used to determine BA and BE are listed in Title 21 of the Code 
of Federal Regulations (CFR). BA and BE are covered under part 320 of the regulations. 
According to the section, the following test procedures, in descending order of preference are 
acceptable as evidence to determine the BA and BE of a drug product [30]: 
A. In vivo (clinical) studies determining the concentration of drug (and/or its active 
metabolites) in the blood/plasma/serum or another appropriate biological fluid 
as a function of time. If there is an in vitro test that has been correlated with and 
is predictive of human in vivo bioavailability data, it can be used in lieu of in 
vivo studies.  
B. In vivo (clinical) studies where the concentration of API/active metabolites are 
measured in the urine as a function of time can also be used as a measure of BA 
and BE. FDA recommends the time intervals to be as small as possible in order 
to effectively estimate the rate of elimination of the drug. This approach is not 
appropriate for drugs that are not excreted primarily in the urine. 
C. A third way to determine BA and BE is by using pharmacological end points. 
This in vivo approach is used when there is no method to determine the 
concentration of API in biological fluids or excretory products. There should, 
however, be a well-established method to determine the acute pharmacological 
effect. BA determination by pharmacological studies is suitable for use of drugs 
that are administered for local use. 
D. The least accurate method as described by the FDA is that of well-controlled 
clinical trials comparing the safety and efficacy of two drug products. This 
method is accepted when previous approaches cannot be used. Accepted 
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application of this technique is for locally administered products which are not 
intended to be absorbed, e.g.: topical preparations and inhaled bronchodilators. 
Periodontal microparticles such as Arestin® and their generic products can also 
be considered in this category. 
E. An in vitro test (usually the dissolution test) which is currently available and 
accepted by the FDA. This test should ensure that the drug product has a 
suitable in vivo human BA. 
F. Any other approach that the FDA deems fit to establish BA and BE of drug 
product. 
1.1.3.3 Bioequivalence Testing According to the Biopharmaceutics Classification System 
In the past two decades, the role of dissolution testing in determining BA and BE has 
increased considerably. This is a result of the introduction of the Biopharmaceutics Classification 
System (BCS). The BCS classification of drug substances was introduced by G. L. Amidon. 
According to the BCS, drug substances can be divided into four categories as follows: Class I – 
high solubility, high permeability; Class II – low solubility, high permeability; Class III – high 
solubility, low permeability; and Class IV – low solubility, low permeability [31]. In context of 
biowaiver applications, a drug is said to be ‘highly soluble’ when the highest strength of the API 
in a drug product is soluble in 250 mL or less of aqueous media at 37  1 °C within the pH range 
of 1 – 6.8 [32]. A ‘highly permeable’ drug has a systemic BA (or extent of absorption) of 85 % or 
more of an administered dose, provided the drug is stable in the gastrointestinal (GI) tract. Besides 
solubility and permeability, the FDA considers dissolution as a third parameter when assessing 
biowaiver requirements. The FDA suggests that it will consider applications to grant biowaivers 
to manufacturers for BCS Class I or Class III drugs when formulated in an IR product.  
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1.2 Development and Validation of Dissolution Methods 
Development of reliable dissolution method is therefore an important step in the product 
development and approval process. Dissolution method development involves optimization of a 
number of variables, such as the type of dissolution apparatus, dissolution media and volume, 
agitation/flow rate, sampling times, temperature and analytical procedure [13]. The most important 
steps in development of a dissolution method are the selection of an apparatus and the 
determination of which dissolution media will be used, as described in the following paragraphs. 
1.2.1  Types of Dissolution Testing Apparatus 
Dissolution tests can be carried out in a variety of apparatuses, depending on the type of 
drug product that needs to be tested. However, to standardize the dissolution tests worldwide, 
regulatory agencies compiled a list of official dissolution apparatuses. There are seven types of 
dissolution apparatuses that are listed in the USP. The first four types of official dissolution 
apparatuses (Apparatus I – IV) are listed in USP general chapter 711 [33]. This chapter is 
harmonized with the Japanese Pharmacopoeia and European Pharmacopoeia. USP Apparatus V – 
VII are listed in general chapter 724 [34]. These three apparatuses are intended for testing of 
transdermal systems and are not accepted by the European and Japanese pharmacopoeias. The 
seven official USP apparatuses are tabulated in Table 1 and an illustration of their agitation 
assembly is presented in Figure 3.  
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Table 1. List of Official Dissolution Apparatus, their Properties and Applications [35]  




Apparatus I – Basket 25 – 50 rpm 500 – 4000 mL Capsules, tablets 
Apparatus II – Paddle 25 – 150 rpm 500 – 4000 mL 
Capsules, tablets, 
suspensions 
Apparatus III – 
Reciprocating Cylinder 






Apparatus IV – Flow 
Through Cell 
NA 
Up to 50 
mL/min 
Any dosage form, with 
appropriate 
modification 
Apparatus V – Paddle 
Over Disk 
25 – 150 rpm 500 – 4000 mL Transdermal patch 
Apparatus VI – 
Cylinder 
50 rpm 500 – 4000 mL Transdermal patch 
Apparatus VII – 
Reciprocating Holder 









Figure 3. Illustration of Agitation Assemblies of USP Apparatuses. (A) Apparatus I – Basket, (B) Apparatus II – 
Paddle, (C) Apparatus III – Reciprocating cylinder, (D) Apparatus IV – Flow through cell, (E) Apparatus V – Paddle 
over disk, (F) Apparatus VI – Cylinder, (G) Apparatus VII – Reciprocating holders 
1.2.2  Types of Media Used for Dissolution Testing 
The FDA recommends all dissolution tests to be carried out using aqueous media [36]. 
However, the choice of media depends on the purpose of dissolution testing. In general, types of 
dissolution media used for dissolution testing can be classified as non-biorelevant and biorelevant.   
1.2.2.1 Non-Biorelevant Dissolution Media 
When a dissolution test is carried for routine quality control purposes, non-biorelevant 
media are generally used [37]. Such dissolution tests are conducted mainly to obtain dissolution 
profiles of drug products and are not intended for determining in vitro-in vivo correlations 
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(IVIVC). Usually, the limited buffering capacity of pure water discourages its use as a dissolution 
media. Many a times, researches use pH-adjusted aqueous solutions that mimic the pH of stomach 
(1.2) for dissolution testing. Thus the use of 0.1 N HCl solution recommended by the FDA to 
simulate the gastric pH is a non-biorelevant dissolution medium [21]. The volume of media 
employed is usually either 500, 900 or 1000 mL in compendial methods. Surfactants such as 
sodium lauryl sulfate and tween are often used to maintain sink conditions for drugs exhibiting 
poor aqueous solubility.  
1.2.2.2 Biorelevant Dissolution Media 
Biorelevant media are those media which mimic the fluid present at a particular site, at 
least to some extent. In 2015, Markopoulos, C. and colleagues classified biorelevant media into 
four categories [38]. Level 0 biorelevant media are those which mimic just the pH of the system. 
Such media were proposed to have some buffer capacity (not necessarily biorelevant) that could 
maintain the pH of the system. Under this classification, a pH 6.8 buffer media that is 
recommended by the FDA to mimic the pH of the intestine can be considered to be biorelevant 
[21]. Level I biorelevant media simulate the pH and buffering capacity present in vivo. 
Consideration of fasted and fed states comes into account as the fed conditions influence buffering 
capacity. Level II biorelevant media contain bile salts, lipids and other digestion products. The 
osmolality of the solution, along with composition is mimicked. Level III biorelevant media most 
closely mimic the fluid present in the body. They are similar in pH, buffer capacity, composition, 
osmolality, protein and enzyme content as well as viscosity [38].  
The most commonly used biorelevant media simulate the gastro-intestinal environment. 
There are biorelevant media which mimic both the fasted and fed states of the stomach and small 
intestine [37, 39]. Over time, media mimicking the fluids present in various regions, such as 
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synovial fluid [40], vaginal fluid [41], colonic fluid [42] and lung fluid [43] among others have 
been reported. Marques, M. R. C. and colleagues reviewed the various biorelevant dissolution 
media that can have potential applications in dissolution testing of drug products [43]. 
1.2.3  Validation of Dissolution Methods 
The guidelines for validation of dissolution methods are more general than those for 
chromatographic methods. The USP Chapter 1225 on Validation of Compendial Procedures [16] 
categorizes analytical procedures into four different categories. Each category has different 
requirements for validation. According to this chapter, dissolution methods need to be validated 
for precision. Other parameters such as accuracy, specificity, limit of detection and quantitation, 
linearity and range may be done, depending on the specific dissolution test. USP Chapter 1092 on 
The Dissolution Procedure: Development and Validation [13] gives a more detailed guideline on 
validation of dissolution tests. Some parameters that should be checked while validating 
dissolution methods include the discriminatory potential, specificity, linearity, accuracy, precision, 
robustness, filter compatibility and stability of sample.  
1.3 Dissolution Testing of Micro/Nano-particulate Systems 
A closer look at the various apparatuses and media would suggest that most of the methods 
are designed to test drug release from oral solid dosage forms. These methods are usually not 
suitable to test drug release from micro- or nanoparticulate systems. Thus, there have recently been 
efforts to develop methods to assess drug release from particulate dosage forms. Dissolution 
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methods used for particulate systems were first classified by D’souza S. S. and DeLuca P. P. to be 
of the following three types: sample and separate, dialysis-based methods and continuous flow 
methods [44].  
1.3.1  Sample-and-Separate Type Methods 
Sample and separate based methods are the most commonly used dissolution methods for 
release testing of particulate systems [44, 45]. In sample and separate procedures, micro- or 
nanoparticles are added to tubes containing a suitable dissolution medium. These tubes are exposed 
to the desired temperatures and may be agitated during the test. Sampling of media is conducted 
at predetermined times by separating the particles from the media. Separation of microparticles is 
carried out by either filtration or centrifugation of the solution. After sampling, new media is added 
to the tubes to maintain sink conditions and dissolution volume [46]. 
Sample-and-separate methods provide flexibility in the amount of media that can be used 
for drug release testing. Methods reported in literature use either tubes or bottles and vary greatly 
in volume of media that is used for testing [45]. Media volumes of 1 mL [47, 48] to more than 100 
mL [49, 50] can be used for drug release testing. Multiple modes of agitation (if desired) can be 
used in the methods. This is a simple method and can be carried out in almost every laboratory 
setting without the need of specialized equipment. However, the most common problem with this 
method is the loss and/or destruction of particles during sampling. Both filtration and 
centrifugation are unsuitable techniques for separation of particles from the dissolution media. 
Another issue that is often encountered with this technique is aggregation of microparticles [51]. 
Hydrolyzed polymers can clog filters and centrifugation can disrupt particle structure, giving 
unreliable results. 
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1.3.2  Dialysis-Based Methods 
Dialysis methods were initially used for drug release testing of oily and liquid formulations 
[44]. Using dialysis-based methods to test drug release from microparticles helps in overcoming 
the problems involved with separation in the sample-and-separate methods. Briefly, in dialysis 
methods, the formulation to be tested is physically separated from the sampling media with the 
help of a dialysis membrane. Originally, the formulation to be tested was added to dialysis sacs, 
which was exposed to the dissolution media and maintained at an appropriate temperature [51]. 
The bulk media is generally agitated to assist drug diffusion from inside the dialysis sac [44]. Sink 
conditions are better maintained when the ratio of bulk fluid to fluid inside the dialysis sac is 5-10 
[45]. In order to avoid interference of dialysis membrane in drug release, it is recommended that 
the molecular weight cut off (MWCO) of the membrane should be at least 100 times the size of 
the compound [52]. 
Although dialysis methods are convenient to measure drug release of particulate systems, 
they are often criticized for inadequate agitation and violation the sink conditions within the 
dialysis sacs [51]. In order to avoid sink violations, reverse dialysis methods were introduced, 
where microparticles are suspended in the outer bulk media and samples are taken from inside the 
dialysis sac. Reverse dialysis methods have been shown to have lesser variability than dialysis 
methods [53] but may lead to loss of sample [45]. In general, both dialysis and reverse dialysis 
membranes require a large amount of media to maintain sink conditions.  
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1.3.3  Continuous Flow Methods 
Continuous flow methods involve the use of a flow through cell. Typically, particles are 
added to a cell and the desired media is made to flow through the cell with the help of pumps. 
Media can be allowed to flow either without re-circulation (open loop) or with re-circulation 
(closed loop). Like the previous methods, continuous flow methods provide flexibility to use the 
desired media volume for drug release studies [46]. As reported in literature, continuous flow 
methods can be used in various configurations. One of the earliest tests involved dispersing 
microparticles in filtration cells and passing media continuously through the cells at a constant 
flow rate [54]. Aubert-Pouëssel, A. and coworkers developed a method where microparticles were 
dispersed in unpacked high-performance liquid chromatography (HPLC) tubes and incubated at 
37°C. Media was continuously circulated through the cells at 5 µL/min and was collected in a 
refrigerated chamber where samples were stored prior to analysis [55]. The microparticles tested 
in this method were not separated from the dissolution media. Since microparticles are not 
separated from the continuously flowing media, the released polymer and/or the particles 
themselves may block the filter, causing irregular of flow rates during the test.  
The most recently applied continuous flow dissolution method used to measure drug 
release from particulate systems utilizes the USP IV apparatus. It is currently the preferred method 
for drug release testing [46] and provides several advantages such as greater lab-to-lab uniformity, 
decreased aggregation of particles, and flexibility in the flow rate, volume and type media used. 
The USP IV apparatus can also be run in various configurations. In some configurations, 
microparticles are added to flow through cells and glass beads are used to prevent aggregation of 
particles, achieve a laminar flow and decrease the dead volume inside the cell [56]. Use of a filter 
on the exit side of the cell allows for separation of particles from the released drug. However, 
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polymers can settle in the tubes, blocking tubes and causing irregularities in the flow [46]. More 
recently, a dialysis enclosure has been used to physically separate microparticles from the 
dissolution media [57]. This technique combines the advantages of the dialysis-based techniques 
with those of continuous flow methods.  
Another advantage of continuous flow-based methods is that a broad range of flow rates 
can be used for media circulation. Depending on the flow rate required, three types of pumps are 
used for continuous flow dissolution methods. HPLC pumps are used to achieve low flow rates of 
0.4 mL/min [58] and peristaltic pumps are used for re-circulation and higher flow rates up to 30 
mL/min [59]. Syringe pumps are generally used when extremely low flow rates are required. One 
of the lowest flow rates that has been used for drug release of microparticles is 5 µL/min [55]. 
Most of the methods for drug release testing of particulate systems have been developed 
for testing injectable micro- or nanoparticles. They are usually carried out at high flow rates and 
relatively low media volumes to simulate the site of injection [60]. Since parenteral microparticles 
are designed to release the drug over extended periods of time, most of the research efforts focus 
on developing accelerated methods to study drug release from microparticles in a shorter time 
span. Researchers have developed accelerated continuous-flow methods for parenteral 
microparticles by using elevated temperatures [61], acidic [62] or alkaline [63] pH and changing 
the ionic strength [64].  
There have been minimal efforts to design drug release testing methods for microparticles 
under biorelevant conditions. The dispersion releaser technology was recently introduced to test 
drug release from micro- and nanosized carriers. It is a dialysis-based device comprising of a 
slotted sample holder which is wrapped with a dialysis membrane [65]. This device is magnetically 
attached to the mini-paddle set-up of the mini-vessel assembly [66]. Jung, F. and coworkers 
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compared the dispersion releaser technology to filtration-based drug release testing using 
biorelevant release media [67]. A physiologically-based pharmacokinetic model (PBPK) was 
developed and tested for both the methods. Although the filtration-based method was faster, the 
dispersion releaser technology could discriminate between slight changes in the formulation, 
providing better discriminatory potential. 
1.4 Dissolution Testing of PLGA-based Micro-/Nanoparticles 
PLGA is a synthetic aliphatic copolymer of poly(lactic acid) (PLA) and poly(glycolic acid) 
(PGA). PLGA is available in a wide range of lactic acid-to-glycolic acid ratio (LA:GA) and 
molecular weights (Mw) of 10 – 200 kDa [68]. PLGA is a very versatile, biodegradable and 
biocompatible polymer approved by the FDA for human use. The versatility of PLGA stems from 
the ease with which properties of the polymer can be manipulated to obtain a suitable release 
profile. Some of the properties that affect the release of drugs from PLGA-based systems are listed 
below: 
A. LA:GA Ratio: PLA contains a methyl group in its structure, making it more 
hydrophobic in nature as opposed to PGA, which lacks the methyl group. Thus, 
increase in LA:GA ratio of PLGA increases the hydrophobicity of the polymer and 
results in lower rate of drug release [69]. 
B. Polymer Crystallinity and Glass Transition: In general, when drug release is controlled 
by diffusion, increase in polymer crystallinity and glass transition temperature (Tg) 
decreases the rate of drug release [70]. PLGA can be prepared using poly(L-lactic acid) 
(PLLA), which is highly crystalline or poly(D-lactic acid) (PDLA), which is 
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completely amorphous or a mixture of the two forms. Although GA is more crystalline 
in nature, it reduces the overall crystallinity of PLGA. Thus, higher LA content causes 
an increase in crystallinity of the final PLGA, leading to decrease in rate of drug release 
[71]. Higher LA content, in addition to its effect on hydrophobicity, also increases the 
Tg of the polymer, reducing polymer chain motility and rate of drug release [70]. 
C. Molecular weight of PLGA: Increase in Mw of PLGA causes increase in Tg and 
hydrophobicity. Thus, higher Mw PLGA releases drug more slowly than lower Mw 
PLGA [72, 73]. It is important to note that higher Mw PLGA degrades at a faster rate 
than lower Mw PLGA due to more sites of hydrolysis. However, polymer degradation 
affects drug release at a later stage than diffusion. Thus, the effect of faster polymer 
erosion in case of higher Mw PLGA is countered by more drug diffusing out of the 
particles during the initial phase in case of lower Mw PLGA [69]. 
D. Size of Matrix: Autocatalysis of PLGA is one of the major mechanisms of drug release 
from PLGA systems. There are two processes countering each other during PLGA 
hydrolysis. First is the formation of acidic components which causes further hydrolysis 
of PLGA. Second in the influx of relatively basic release media, which neutralizes the 
acidic moieties [71]. Microparticles with a larger particle size have a longer diffusion 
path which reduces the rate of influx of basic moieties. Thus, larger microparticles are 
expected to increase the rate of drug release from PLGA microparticles. 
E. Type of Drug: Hydrophilic drugs diffuse through water-filled pores and hydrophobic 
drugs diffuse through the polymer. Diffusion through the polymer is usually slower 
than diffusion through water [74] and it has been shown previously that hydrophobic 
drugs show lower rates of drug release than hydrophilic drugs [75]. Weakly acidic and 
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basic drugs can also impact drug release from PLGA systems. Acidic drugs decrease 
the pH inside particles, increasing the PLGA hydrolysis. Basic drugs can either increase 
PLGA hydrolysis increasing the rate of drug release or neutralize the hydrolysis 
products and reduce drug release rate [71]. Further, time-dependent changes in pH 
within PLGA microparticles can affect drug ionization and charge-based interaction 
with PLGA. Drugs molecules are also known to interact with PLGA, altering the rates 
of drug release in these special cases. For example, Klose and coworkers [76] showed 
that ibuprofen (slightly acidic) has a much faster rate of drug release than lidocaine 
(slightly basic). This was attributed to the interaction of positively charged lidocaine to 
the negatively charged PLGA end groups.  
F. Drug Loading: Generally, microparticles which contain higher amount of drug show 
greater drug release. This is because the ratio of oligomer-to-drug is lower in particles 
with higher drug loading [72]. However, when a basic drug is encapsulated in PLGA 
systems, the Tg of the product increases with increase in drug loading. This is because 
basic drugs interact with PLGA, increasing matrix rigidity. Thus, the rate of drug 
release reduces with an increase in drug loading [77]. 
G. Fabrication Technique and Sterilization: Various formulation and process parameters 
can significantly affect the characteristics of the PLGA particles [78]. Porosity of the 
particle is highly influenced by the manufacturing technique [79]. Increase in porosity 
increases the mobility of drug molecules leading to an increase in drug release. Increase 
in porosity can also change drug release mechanisms. In comparison to large porous 
particles, smaller porous particles display increased rate of drug release [80]. This is 
because drug molecules in smaller porous particles have access to more media and 
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surface area for drug release as compared to non-porous molecules, which require the 
polymer to degrade to release the drug.  
1.4.1  Mechanisms of Release from PLGA-based Systems 
Although there are various factors that affect the release of drug from PLGA matrices, the 
actual mechanisms of drug release are limited. The “true” mechanisms of drug release, as 
summarized by Fredenberg, S. and colleagues [74] include: 
A. Diffusion through water filled pores is most common during the initial phase of drug 
release. Molecules diffuse through the water present in the pores in the matrix through 
random movements. This transport is driven by concentration gradient and is dependent 
on the porosity of the matrix.  
B. Osmotic pumping occurs usually in a non-swellable matrix. This phenomenon is a 
result of water absorption, which increases the osmotic pressure inside the particle. In 
this case, the drug releases out of the particle due to convection and not diffusion. 
Osmotic pumping is not a very commonly-observed mechanism of drug release in 
PLGA-based systems as PLGA has mobile chains which allow for swelling. However, 
it has been reported in literature in cases of hydrophobic (LA:GA ratio of 85:15) and 
high molecular weight (> 300 kDa) systems [81]. 
C. Diffusion through polymer occurs in cases of very small hydrophobic molecules. The 
molecules partition into the polymer and travel through the polymer chains to the 
surface of the matrix. From there, the molecules need to dissolve in water before they 
can be released. Diffusion through polymer chains is not dependent on the porosity of 
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the matrix. However, increased porosity affects the overall release rate by increasing 
the rate of drug dissolution in water. 
D. Polymer erosion is the main mechanism of drug release for low Mw PLGA systems. 
Polymer erosion is the hydrolytic cleavage of polymer chains leading to production of 
smaller oligomers. Once the polymer matrix erodes, the encapsulated drug is exposed 
to dissolution fluid, causing release of drug. This mechanism is especially important 
for high Mw drugs that cannot diffuse through the polymer or water to get released.  
1.4.2  Methods to Determine Drug-Release from PLGA-based Micro-/Nanoparticles 
Since there are a number of PLGA-based products in the market, the polymer is popular 
among researchers for investigation. This has driven the development of a number of approaches 
to test the drug-release from PLGA-based systems. The methods used to evaluate drug-release 
from PLGA micro- and nanoparticles can be categorized into sample-and-separate, dialysis-based 
and continuous flow methods. Most methods used for PLGA-based systems can be used for drug-
release testing of other microparticles and are summarized in the previous section. The 
development of accelerated drug-release testing methods is popular amongst PLGA microparticles 
as well. The USP IV apparatus is being increasingly used and explored for determining drug-
release from PLGA-based particulate systems. Particles are either dispersed with glass beads in 
dissolution cells [56] or placed in a dialysis adapter [57]. Dissolution tests are run either under 
“real-time” (37°C) or accelerated conditions, such as increased temperature [56, 61].  
The dialysis adapter combines the advantages of dialysis and continuous flow methods. It 
helps in separating particles from the release media, reducing problems of filter blockage. The 
USP IV method is preferred over other methods as it is a standardized equipment, enabling the 
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lab-to-lab transferability [56]. The USP IV method has been reported to simulate the subcutaneous 
environment present in clinical settings as the media in the environment is continuously 
replenished [82]. Thus, the USP IV apparatus is very suitable for drug release testing of parenteral 
PLGA particles which are administered subcutaneously.  
However, despite all these efforts, there is a lack of biorelevant dissolution testing methods 
for microparticles that are intended to be administered in extremely small cavities, such as the 
periodontal and ocular pockets. There is thus a need for development of a small volume apparatus 
(SVA) that can be reliably used for drug release testing of particulate formulations intended to be 
delivered in small cavities.  
 30 
2.0 Project Goal and Approach 
2.1 Project Goal 
Based on the current need for development of small volume dissolution apparatus, the goal 
of my project was to develop a biorelevant dissolution method for microparticulate systems 
intended to be delivered in small cavities. A rapid screening method utilizing the USP IV apparatus 
was also developed. The specific aims of my project were: 
A) To evaluate the discriminatory potential of the rapid screening and biorelevant 
dissolution methods 




Figure 4. Overview of Approach Taken to Achieve Project Goal 
2.2.1  Model Drug Product 
The overall approach undertaken in order to achieve the project goal is summarized in 
Figure 4. In order to develop and demonstrate the applicability of a small volume dissolution 
apparatus, microparticles applied in the periodontal pocket were selected. Specifically, 
minocycline hydrochloride (MIN), an antibiotic, loaded PLGA-based microparticles were 
evaluated. These microparticles are used in periodontitis. Periodontitis affected about 64.7 million 
people (46 % of the population) between 2009-2012 in United States alone [83]. It is a chronic 
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bacterial inflammation of the epithelial and connective tissues that surround and support the teeth 
[84]. In healthy adults, the gap between these periodontal tissues and the tooth is 1-3 mm [85]. 
One of the hallmarks of periodontal disease is increase in pocket depth and formation of a 
periodontal pocket [86]. Figure 5 illustrates the differences between a healthy and inflamed 
periodontal pocket.  
 
Figure 5. Differences between a healthy and inflamed periodontal pocket. Reproduced with permission [84]. 
Various studies show a positive correlation between the volume of the periodontal pocket 
and the stage of periodontal disease [87-89]. The pocket volume varies from 0.4 µL to 1.5 µL 
depending on stage of disease [90]. The periodontal pocket is filled with a physiological and 
inflammatory exudate, called the gingival crevicular fluid (GCF). The composition of GCF is 
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similar to that of any inflammatory exudate with lower protein content [91]. The flow of GCF is 
highly variable and ranges between 0.33 – 0.73 µL/min [90]. 
The most common and effective treatment of periodontitis is scaling and root planing 
(SRP). It is often accompanied with administration of antibiotics either locally or systemically. 
Tetracyclines, doxycycline, metronidazole, amoxicillin, ciprofloxacin and macrolide antibiotics 
are reported to be useful as systemic antibiotics in periodontitis [92]. To avoid problems of 
systemic antimicrobial resistance and side effects, focus was shifted to locally administered 
antimicrobial therapy [93]. The first locally acting system for periodontitis was ActisiteTM, which 
was comprised of tetracycline-loaded fibers that were wound around the affected teeth. Since then, 
various films, gels, chips, cubes and micro- or nanoparticles have been studied for management of 
periodontitis [94].  
In the current study, we used Arestin® as a model drug product for the development of 
dissolution methods. Arestin® is manufactured by OraPharma and is composed of PLGA 
microspheres encapsulating 1 mg of MIN, a bacteriostatic agent. Arestin® is shown to maintain 
therapeutic levels in the periodontal pocket for a period of 14 days [95]. Clinical studies have 
shown Arestin® in conjunction to SRP is more effective than SRP alone [96]. Another study 
compared the effectiveness of Arestin® and Elyzol (25 % metronidazole gel) as adjunct treatments 
in periodontitis. At 3 months, only the Arestin®+SRP group showed a statistically significant 
increase in clinical attachment level and reduction in pocket probing depth [97]. Thus, Arestin® 
has been shown to be an effective strategy for management of periodontitis and has been available 
in the market for almost two decades. The physicochemical properties of the two main components 
of Arestin®, MIN, the active agent and PLGA, the release controlling polymer are listed below. 
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2.2.1.1 Minocycline Hydrochloride – Active Pharmaceutical Ingredient 
 
Figure 6. Structure of Minocycline Hydrochloride 
Table 2. Properties of Minocycline Hydrochloride [98] 
Molecular weight 493.941 g/mol 
Molecular formula C23H27N3O7.HCl 
Class Tetracyclines (semi-synthetic) 
Mechanism of action Inhibition of protein translation 
Water solubility 52,000 mg/L at 25°C 
Log Kow 0.05 
pKa 2.8, 5.0, 7.5, 9.6 [99] 
Stability 
Stable in air; sensitive to heat, light, and 
oxidation. Degrades in acidic and basic 
conditions (pH 0.38 – 9.35) [100] 
 
2.2.1.2 Poly (lactic-co-glycolic acid) – Release Controlling Polymer 
As reviewed earlier, PLGA is a versatile polymer that has been used in multiple products 
which are currently in the market. Being FDA approved, the polymer finds applications in a wide 
variety of fields, from drug delivery to bone regeneration. Like in other PLGA-based systems, the 
role of PLGA in Arestin® is to control the rate of MIN release. Based on the results of reverse 
engineering of Arestin® (unpublished data), Arestin® is composed of PLGA with LA:GA ratio of 
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50:50. The polymer has acid-end groups and molecular weight of about 24 kDa. Arestin® 
microparticles encapsulate 25 % w/w of MIN. The slow degradation of PLGA inside the 
periodontal pocket helps in maintaining the concentration of MIN above therapeutic levels in the 
pocket for at least 14 days [101]. 
2.2.2  Development of Comparators to Challenge Developed Methods 
The discriminatory ability of dissolution methods is generally assessed by testing the 
effects of deliberate changes in manufacturing of the products on dissolution characteristics [102]. 
Thus, a panel of microparticles with deliberate changes in composition were prepared (unpublished 
data). These microparticles were prepared by varying the LA:GA ratios, Mw of PLGA and MIN 
drug loading and were expected to show differences in drug release.  
Additionally, a panel of microparticles with similar composition to Arestin® but prepared 
using different manufacturing conditions, specifically stir rate and solvent ratio were prepared. 
These microparticles were tested on the USP IV method to evaluate if the method can detect 
differences based on manufacturing differences. All microparticles were designed, fabricated and 
characterized for particle size by Ms. Ashlee C. Greene in Dr. Steven R. Little’s research group 
(Swanson School of Engineering, University of Pittsburgh).  
2.2.3  Development of Dissolution Methods 
Currently, the USP method for dissolution testing of periodontal systems containing MIN 
utilizes a tube rotator equipment. Briefly, one dose of the periodontal system is dispensed in a 15 
cm long glass tube between two 25 µm screens. 10 mL of phosphate buffer (pH 4.2) is added to 
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the tubes and they are sealed with a snap-seal closure made of Teflon. The tubes are rotated in the 
tube rotator and the entire assembly is maintained at 37°C. Samples are taken at 4 h, 24 h, 48 h 
and 72 h by total medium replacement. The amount of MIN in dissolution samples is calculated 
using a liquid chromatography method at 280 nm [103]. The acceptance criteria as give in the USP 
monograph is as follows: 






to be Released (µg) 
Cumulative Amount 
to be Released (µg) 
Calculated % 
Released (Ideal) 
0 – 4  NLT 25 NLT 100 NLT 100 NLT 10 
4 – 24 NLT 1 NLT 20 NLT 120 NLT 12 
24 – 48 NLT 0.2 NLT 4.8 NLT 124.8 NLT 12.48 
48 – 72  NLT 0.05 NLT 1.2 NLT 126 NLT 12.6 
*Note: NLT = Not less than 
Tariq M. and colleagues reviewed the numerous methods that have been used for drug 
release testing of periodontal systems in vitro [104]. A variety of dissolution media, from distilled 
water to simulated salivary fluid, human serum and hydroalcoholic solutions have been reported 
in literature. The media volumes also vary greatly, from 1 mL to 500 mL. Continuous flow 
methods with flow rates ranging from 0.65 mL/min to 10 mL/min have been used for testing. 
However, none of the methods simulated the extremely low fluid volumes and flow rates present 
in the periodontal pockets. The current work was focused on bridging this gap between in vitro 
evaluation settings and in vivo release conditions.  
First, a rapid screening method based on a previously reported USP IV method [57] was 
developed. This method was used to test drug release from the prepared microparticles and to 
ascertain that the microparticles produced broad differences in dissolution profiles. After 
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confirming that the microparticles showed differences using the USP IV method, the novel small 
volume method (SVM) was evaluated using these microparticles. 
The SVM was developed on a small volume apparatus (SVA) which was designed 
previously in our lab (Invention Disclosure Number 04686). The apparatus (Figure 7) consists of 
an inner slotted chamber and outer closed chamber. The inlet and outlet caps are designed to allow 
unidirectional flow of media, allowing the assembly to function like a flow-through cell. The 
assembly is connected to a syringe pump which allows for continuous media flow in an open-loop 
configuration. These flow through cells can be placed in an oven to regulate the temperature.  
 
Figure 7. Images of the Small Volume Apparatus. (A) Inlet cap, (B) Outlet cap, (C) Outer chamber, (D) Inner 
chamber with dialysis membrane, (E) Assembled device 
A GCF simulant (sGCF) was also developed in the laboratory. The sGCF was used as a 
biorelevant media for the SVM. Table 4 lists the composition of the sGCF and Table 5 compares 
the composition of sGCF and human GCF.  
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Table 4. Composition of GCF Simulant 
Component Amount (g/L) Amount (mM) 
Citric acid monohydrate 0.338 1.608 
Trisodium citrate dihydrate 5.411 20.968 
Sodium chloride 6.740 115.332 
Potassium chloride 0.719 9.644 
Bovine serum albumin 0.056 0.001 
Calcium chloride dihydrate 0.490 3.333 
MilliQ water 1 L - 
 
Table 5. Comparison between sGCF and human GCF [105] 
Component Human GCF sGCF 
Sodium (mEq/L) 174.7 ± 18 174.5 
Potassium (mEq/L) 9.54 ± 2.4 9.52 
Calcium (mEq/L) 5.41 ± 0.37 5.44 
pH 6.8-8.7 7.2 [106] 
 
2.2.4  Development of Analytical Methods 
MIN is sensitive to heat, light and oxidation [107]. About 10 % MIN degrades within an 
hour in phosphate buffered saline (PBS) at 37°C [108]. The degradation of MIN poses a challenge 
in the development of UV assay methods for quantitation of MIN in dissolution samples. It has 
been reported that for unstable drugs, UV analysis can be carried out at isosbestic point [109]. The 
isosbestic point is the wavelength at which the total absorbance of the sample does not change 
during a chemical reaction or when the sample undergoes a physical change [110]. Simply put, at 
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the isosbestic point, the total absorbance of the sample depends on the total molar concentration 
of two or more species in equilibrium.  
Isosbestic point analysis has been used in the compendial dissolution method for Aspirin 
tablets [111]. Previous reports have demonstrated that tetracycline hydrochloride also displays an 
isosbestic point and that analysis of tetracycline and its degradants can be carried out at the 
isosbestic point without separation of the components [112]. Yang, Z. and coworkers reported to 
have analyzed MIN dissolution samples using UV-Visible spectroscopy without chromatographic 
separation of the degradants [113]. This indicates that MIN may exhibit an isosbestic point, which 
can be used for UV analysis of MIN samples. Thus, an online UV-based analytical method was 
developed for analysis of MIN samples using the USP IV method. The dissolution samples 
obtained using the biorelevant dissolution method were evaluated using a liquid chromatography 
based-assay.  
A brief account of the development of analytical methods is presented in chapter 4. 
Chapters 4 and 5 also demonstrate the development and testing of the USP IV method and SVA 
using the developed microparticles as well as Arestin®. Specifically, Arestin® was utilized during 
method development and to test the reproducibility of the methods. The discriminatory ability of 
the method was evaluated using the developed microparticle panel(s).  
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3.0 Materials and Methods 
3.1 Materials 
Minocycline hydrochloride was purchased from Sigma Aldrich. Citric acid monohydrate, 
sodium hydroxide, sodium chloride, sodium citrate, bovine serum albumin, calcium chloride 
dihydrate, sodium azide and dimethyl sulfoxide were purchased from Spectrum Chemical. 
Potassium phosphate monobasic, potassium chloride, acetonitrile, ethanol and phosphate buffered 
saline (10x) were procured from Fisher Scientific. Tetra butyl ammonium hydrogen sulphate 
(98%) was obtained from J. T. Baker®. Float-A-Lyzer® G2 devices of 50 kDa MWCO and 
dialysis tubing (1 cm flat length, 50 kDa MWCO) were obtained from Spectrum Laboratories. 
Tygon tubing of 5/32” and 1/8” outer diameter was obtained from Fisher Scientific while tubing 
of 0.09” outer diameter was obtained from Cole-Parmer. All small volume chambers were 
manufactured by Mr. James Scott Macpherson at Swanson School of Engineering, University of 
Pittsburgh. 
3.2 Fabrication of MIN loaded PLGA Microparticles 
A panel of microparticles (Panel A), prepared using different process parameters, were 
prepared using the single emulsion method. Another panel of microparticles having differences in 
formulation (Panel B) were also prepared.  The microparticles in Panel A were prepared using 
PLGA of Mw 24 – 38 kDa. The ratio of PLGA:dichloromethane (DCM) and the stir rate used to 
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prepare the microparticles was varied, as given in Table 6. Panel B (Table 7) was prepared by 
varying the MIN drug loading, Mw and LA:GA ratio of PLGA. All microparticles were prepared 
using the single emulsion technique and were designed and fabricated by Ms. Ashlee C. Greene in 
Dr. Steven R. Little’s Laboratory (Swanson School of Engineering, University of Pittsburgh).  
Table 6. Microparticles Differing in Process Parameters (Panel A) 
Microparticle Name Stir Rate Ratio of PLGA:DCM 
0.025H 1500 0.025 
0.05H 1500 0.05 
0.0625M 1000 0.0625 
0.1L 500 0.1 
 








50L3 50:50 15.4 50 
50H1 50:50 64.14 25 
75L2 75:25 14.2 37.5 
85L1 85:15 21.8 25 
85H3 85:15 43.3 50 
3.3 Characterization of Prepared Comparators 
All microparticles were characterized for particle size, surface morphology, drug content 
and polymer Tg. Particle size and surface morphology were determined by Ms. Ashlee C. Greene. 
Measurements were performed by volume impedance using Coulter Counter (Multisizer 3, 
Beckman Coulter). Surface morphology was tested using scanning electron microscopy (SEM). 
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The microparticles were sputter coated with gold/palladium (Au/Pd) using the Denton Sputter 
Coater and then imaged using the JEOL JSM-6510LV/LGS (JEOL Inc., USA). Drug content was 
measured by dissolving around 10 mg particles (or 2 units of Arestin®) in 100 mL of 20 % 
acetonitrile in MilliQ water. The particles were vortexed and stirred in the dark for 1 hour. The 
solution was then filtered using 0.22 µm teflon syringe filters (RestekTM) and analyzed using the 
ultra-high performance liquid chromatography (UPLC) method described below. The Tg of PLGA 
in microparticles was characterized using differential scanning calorimetry (DSC). 2-5 mg 
microparticles were weighed in aluminum pans and sealed with a sealing press (METTLER 
TOLEDO). The lids were punctured to allow for escape of water. Tg was calculated in a cyclic 
run on DSC 2 STARe System (METTLER TOLEDO). First, the microparticles were heated at 
10°C/min from 25 – 125°C. This was done to remove moisture from the sample. The samples were 
then cooled to 0°C at -10°C/min and heated again to 250°C at 10°C/min. All runs were carried out 
under nitrogen gas at a flow rate of 50 mL/min.  
3.4 Determination of Isosbestic Point 
To determine the isosbestic point of MIN, 25 µg/mL samples of MIN in 0.1 % sodium 
azide in PBS were kept in amber colored vials at 37°C for 5 days. Every day, one vial was removed 
and stored at -80°C. UV absorption spectra of all samples were taken using VISIONpro software 
with a UV spectrophotometer (Evolution 300, Thermo Scientific). 
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3.5 Dissolution of Microparticles by USP IV Method 
A USP IV method was developed based on a previously published method [57]. The media 
pumps were calibrated using water at 10 mL/min for 2 minutes. A % error of less than 5 % was 
accepted. Float-A-Lyzer® G2 devices of 50 kDa molecular weight cut-off (Spectrum 
Laboratories) were prepared by rinsing them first with 10 % ethanol for 10 minutes, then with 
purified water for 30 minutes and finally with 0.1 % sodium azide in PBS (dissolution media) for 
another 30 minutes. About 10 mg microparticles (or two Arestin® cartridges) were added to the 
prepared devices. 1.8 mL of dissolution media was added to the devices before capping them. The 
prepared devices were placed in 22.6 mm flow through cells and dissolution was carried out using 
USP IV apparatus (SOTAX CP7 manual closed loop system). 80 mL of dissolution media served 
as the reservoir and was made to recirculate at 10 mL/min flow rate. The test was carried out at 
37°C for 3 days. At predetermined intervals, the cumulative amount of drug released was measured 
by an online UV spectrophotometer (Evolution 300, Thermo Scientific) at 292 nm. At regular 
intervals, a calibration curve of minocycline hydrochloride in dissolution media was prepared and 
analyzed at 292 nm. The readings were used to determine the E11 value, utilized by the software 
to measure % dissolved values during on-line UV analysis. Figure 8 shows a schematic 
representation of the USP IV-based dissolution method. 
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Figure 8. Schematic Representation of USP IV Dissolution Method 
3.6 Dissolution of Microparticles Using Small Volume Apparatus 
Syringe pumps (KD Scientific) were filled with sGCF and calibrated at 0.5 µL/min. An 
error of <10 % was accepted. The inner chamber of the SVA was wrapped with a dialysis 
membrane of 50 kDa MWCO (Biotech CE, 1 cm flat width, Spectrum Laboratories) using an 
adhesive (Liquid Nails All Purpose Adhesive) and teflon tape. About 10 mg microparticles (or 1 
cartridge of Arestin®) were added to the chamber followed by 250 µL of sGCF. The inner chamber 
was inserted into the outer chamber and sGCF was made to flow through the assembled cell at 100 
µL/min to fill the chamber entirely. Once filled, the flow rate was reduced to 0.5 µL/min. Samples 
were collected daily for at least 14 days and diluted to a final of 20 % of acetonitrile in sGCF. The 
diluted samples were analyzed by UPLC. Figure 9 illustrates the small volume dissolution method. 
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Figure 9. Schematic Representation of (A) Dissolution Cell and (B) Set-up of Small Volume Method  
3.7 UPLC Analysis of Minocycline Hydrochloride 
A UPLC-based assay for MIN was developed in-house. A UPLC system (Acquity, Waters) 
with a TUV detector was used for analysis. An Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm 
 50 mm) maintained at 35°C was used. The mobile phase composed of 76 % of citrate-phosphate 
buffer at pH 7.0 and 24 % of acetonitrile, added gravimetrically. A flow rate of 0.2 mL/min was 
used for the isocratic method. Samples were stored at 7°C throughout the run. Samples were run 
for 10 minutes and calibration standards were run for 7 minutes in the respective matrix. Analysis 
was carried out at 277 nm. 
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3.8 Statistical analysis 
Wherever necessary, the dissolution profiles were compared for similarity using the f1 





Microparticles of both panels were characterized for particle size, surface morphology, 
drug loading and Tg. The particles were evaluated for drug release using the rapid screening USP 
IV method. Microparticles of Panel B were evaluated using the SVM as well. Both dissolution 
methods exhibited discriminatory ability.  
4.1 Characterization of MIN loaded PLGA Microparticles 
All microparticles that were manufactured to challenge the developed methods were 
spherical and had a smooth surface. Figure 10 shows a representative SEM image of Arestin®. 
The characteristics of microparticles in Panel A are summarized in Table 8. The particle size of all 
microparticles of Panel A was found to be 32 µm and 44 µm. The MIN content of these 
microparticles ranged between 9 – 22 % w/w. Figure 11 is a typical curve that was obtained using 
DSC. All microparticles had a Tg between 48 – 55°C, characteristic of the PLGA used. Table 9 
summarizes the properties of Panel B microparticles. All microparticles of Panel B and Arestin® 
had a particle size between 28 µm to 40 µm and drug loading between 9 – 21 % w/w. Overall, all 
microparticles that were prepared had a drug loading between 9 – 22 % w/w, which was found to 
be lower than Arestin® (25 % w/w).  
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Figure 10. SEM Image of Arestin® Microparticles 
 











0.025H 0.025 1500 32.3±10.3 12.24 50.6 51.18 
0.05H 0.05 1500 38.8±9.9  9.2 47.77 50.46 
0.0625M 0.0625 1000 43.2±12.1 12.43 47.28 50.02 
0.1L 0.1 500 39.6±14.9 21.67 46.33 48.95 

















85H 85:15 43.3 33.9 ± 11.9 15.50 51.62 54.28 
85L 85:15 21.8 39.2 ± 11.3 9.9 0 51.93 55.36 
75L 75:25 14.2 36.9 ± 12.8 11.42 45.83 49.36 
50H 50:50 64.14 32.9 ± 10.1 9.10 47.49 50.15 
50L 50:50 15.4 28.7 ± 9.6 21.05 49.05 52.75 
Arestin®  50:50 ~24 28.6±12.3 
(Lot H) 
25.13 ± 0.4  
(Lot F) 
45.87 48.52 
*Particle size data generated by Ms. Ashlee Greene, Dr. Steven R. Little Lab 
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Figure 11. DSC Curve of Arestin® Microparticles. The light blue region represents the curve obtained during the 
first and second heat-cool cycle. The dark blue curve was obtained during the second heating cyle and was used for 
calculating Tg. The peaks at the end of the chromatogram indicate drug degradation. 
 
In order to quantify the released MIN from microparticles during dissolution using USP 
IV apparatus, an online UV-Vis spectrophotometer was utilized. However, rapid degradation of 
MIN precluded use of UV spectrophotometer for drug quantitation. Moreover, chromatographic 
methods were not preferred because the total degradation products cannot be accounted given their 
varied absorptivity. Therefore, to account for the degradation, isosbestic point was determined for 
MIN in the dissolution media. 
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4.2 Determination of Isosbestic Point of MIN 
Figure 12 shows an overlay of the UV spectra of MIN samples (25 µg/mL in 0.1% sodium 
azide in PBS) maintained at 37 °C over a period of 5 days under mild shaking. As can be observed 
from the graphs, the absorption maxima of MIN is 246 nm. The absorbance at this wavelength is 
influenced mainly by the amount of MIN in the sample. Thus, as MIN degrades with time, the 
absorbance at 246 nm decreases. However, the wavelength region from 276 – 312 nm showed 
overlapping UV spectra indicating no or minimal changes in absorbance for samples stored for 
different lengths of time. This region is termed as the isosbestic region. The absorbance of the 
sample in this region is proportional to the total concentration of MIN and its degradants in the 
sample. A wavelength of 292 nm, which lies in the middle of the isosbestic region, was chosen for 
online UV analysis. Absorbances were found to be linear from 0.5 µg/mL – 50 µg/mL at 292 nm. 
This range was used to calculate the E11 value, necessary for on-line UV analysis with the USP 
IV apparatus. E11 is a composite value relating absorbance, path length and concentration of the 
samples. Figure 13 shows an overlay of four calibration curves obtained using UV 
spectrophotometer at 292 nm. The average E11 value obtained was 258.62, with a relative standard 
deviation of 4.05 %. 
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Figure 12. Determination of Isosbestic Region. MIN samples in 0.1% sodium azide in PBS (25 µg/mL) were kept 
at 37°C under mild shaking for a period of 5 days. Samples were collected daily and their UV spectra were obtained. 
All UV spectra showed almost constant absorbance in the region between 276 – 312 nm. This region is called the 
isosbestic region.  A wavelength of 292 nm, which lies in the middle of this range, was chosen for online UV analysis. 
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Figure 13. Overlay of Calibration Curves of MIN (0.5 – 50 µg/mL in 0.1% sodium azide in PBS) used for E11 
Calculation at 292 nm. The E11 values were calculated on different days and using different lots of dissolution 
media. The average E11 values was found to be 258.62, with a relative standard deviation of 4.05 %. 
4.3 Analysis of Samples using the USP IV Apparatus 
USP IV dissolution apparatus was utilized to assess dissolution of MIN solution, Arestin®, 
and the prepared microparticle panels to test the reproducibility and discriminatory ability of the 
method. 
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4.3.1  MIN Solution 
Figure 14 shows the release profile of MIN solution (1 mg/mL) using the USP IV method. 
Complete release (100 %) of MIN was observed within 4 hours and the drug release remains almost 
constant up to 3 days. The release reached a plateau in 6 hours, indicating that the release of MIN 
is not affected by the dialysis membrane. The release remained constant over a period of 3 days, 
suggesting that the isosbestic point can be reliably used to test MIN release from microparticles. 
The greater than 100% release observed is attributed to possible interference from unknown 
degradants formed during degradation affecting the sensitivity of detection. This result further 
supports the use of USP IV method for a semi-quantitative comparison of dissolution profiles. 
 
Figure 14. Release of Minocycline Solution in USP IV Method. MIN solution (1 mg/mL) was added to Float-A-
Lyzer® dialysis devices of 50 kDa MWCO. The dialysis devices were inserted in USP IV flow-through cells and 
incubated at 37°C. Dissolution cells were subjected to a continous flow of 0.1% sodium azide in PBS at 10 mL/min 
for a period of 3 days. At predetermined intervals, samples were analyzed by an online UV-Vis spectrophotometer at 
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isosbestic point. Results are presented as Mean ± SD of n=5 samples. Complete release of MIN was observed within 
6 hours and the release profile remained constant over a period of 3 days. 
4.3.2  Arestin®  
Figure 15 shows the dissolution profile of Arestin® obtained using the USP IV method. 
The release profile resembled zero-order release kinetics for the first 13 hours (70 % drug 
released), after which the release approached a plateau. About 85 % of MIN releases within 1 day 
and complete release is observed within 3 days.  
 
Figure 15. Drug Release of Arestin® Microparticles from USP IV Method. Two units of Arestin® were added to 
Float-A-Lyzer® dialysis devices of 50 kDa MWCO. The dialysis devices were inserted in USP IV flow-through cells 
and incubated at 37°C. Dissolution cells were subjected to a continous flow of 0.1% sodium azide in PBS at 10 mL/min 
for a period of 3 days. At predetermined intervals, samples were analyzed by an online UV-Vis spectrophotometer at 
isosbestic point. Results are presented as Mean ± SD of n=3 samples. About 85 % MIN releases within 1 day and 
complete release is observed at the end of 3 days. 
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4.3.3  Panel A Microparticles (Process Changes) 
The dissolution profiles of Panel A microparticles (process changes) are shown in Figure 
16. Both, 0.05H and 0.1L microparticles release about 70 % of the drug over 3 days but 
demonstrate differences in release profiles. Microparticles 0.05H exhibit a faster release while 
0.1L microparticles release in a more sustained fashion. Microparticles 0.0625M release about 60 
% MIN over a period of 3 days. Microparticles 0.025H release the least cumulative amount of 
MIN, with about 15 % of MIN released over 3 days. Table 10 lists the f1 (difference) and f2 
(similarity) values of the dissolution profiles of Panel A microparticles. f1 and f2 values are 
calculated to statistically evaluate the similarities and differences between dissolution profiles.  f1 
values above 15 and f2 values below 50 indicate that the dissolution profiles are not similar to each 
other. As seen from Table 10,  none of the dissolution curves were found to be f1-f2 similar to each 
other, indicating that the USP IV method could discriminate between microparticles produced 
using different process parameters.  
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Figure 16. Drug Release Profiles of Panel A Microparticles (Process Changes) Obtained Using USP IV Method. 
About 10 mg of microparticles were added to Float-A-Lyzer® dialysis devices of 50 kDa MWCO. The dialysis devices 
were inserted in USP IV flow-through cells and incubated at 37°C. Dissolution cells were subjected to a continous 
flow of 0.1% sodium azide in PBS at 10 mL/min for a period of 3 days. At predetermined intervals, samples were 
analyzed by an online UV-Vis spectrophotometer at isosbestic point. Results are presented as Mean ± SD of n=3 
samples. The USP IV method could successfully discriminate between microparticles of Panel A. 
 
Table 10. Statistical Analysis of Dissolution Profiles of Panel A Microparticles. Numbers in bold denote 
values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
0.025H vs. 0.0625M  233.51 23.97 N 
0.0625M vs. 0.1L 17.40 54.23 N 
0.1L vs. 0.025H 72.50 20.54 N 
0.025H vs. 0.05H 322.88 17.92 N 
0.0625M vs. 0.05H 26.80 45.74 N 
0.1L vs. 0.05H 21.05 43.10 N 
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Previous studies have shown that drug release profiles can be normalized to the total 
amount of drug released in order to compare the mechanism of drug release from dosage forms 
[114-116]. Thus, in order to compare the way in which MIN releases from Panel A microparticles, 
the dissolution profiles obtained using the USP IV method were normalized to the total amount of 
MIN released. Figure 17 shows these normalized dissolution profiles of Panel A microparticles. 
Note that the normalized drug release profile of 0.025H microparticles in very uneven. This can 
be attributed to the low amounts of drug released from the microparticles, which may have fallen 
below the sensitivity of the method. A crude comparison of dissolution profiles indicates that 
increase in stir rate increases the burst release properties of microparticles (Figure 17), while the 
solvent ratio may affect the total amount of MIN that is released from the microparticles (Figure 
16). However, there are multiple variables that can affect the drug release profiles of 
microparticles. Thus, additional information is needed before any conclusions about the effect of 
microparticle properties on drug release profiles can be made.  Nevertheless, normalization of 
drugs release profiles removes bias caused due to differences in cumulative amount of drug 




Figure 17. Drug Release Profiles of Panel A Microparticles Normalized to Total Drug Released. Drug release 
profiles of Panel A microparticles (process changes) that were obtained using the USP IV apparatus were normalized 
to the total amount of MIN released over a period of 3 days. Normalization was carried out to understand the way in 
which MIN releases from the microparticles. Results are reported as Mean ± SD of n=3 samples. A basic comparison 
of dissolution profiles suggests that increase in stir rate causes an increase in burst release from microparticles (as for 
microparticles 0.025H and 0.05H) while reducing stir rate causes a more sustained release (0.0625M and 0.1L).   
4.3.4  Panel B Microparticles (Formulation Changes) 
Figure 18 shows the dissolution profiles of microparticles differing in composition. 
Microparticles 85H released the highest amount of MIN, about 60 %, whereas 85L released the 
lowest amount of MIN. Given the sensitivity limitations of this method, such low drug release 
cannot be quantified. Microparticles 50H, 75L and 50L released about 40 %, 25 % and 10 % of 
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MIN over the test duration. Overall, The USP IV method could successfully discriminated between 
the microparticles of Panel B. 
 
Figure 18. Dissolution Profiles of Panel B Microparticles (Formulation Changes) Obtained Using USP IV 
Method. About 10 mg of microparticles were added to Float-A-Lyzer® dialysis devices of 50 kDa MWCO. The 
dialysis devices were inserted in USP IV flow-through cells and incubated at 37°C. Dissolution cells were subjected 
to a continous flow of 0.1% sodium azide in PBS at 10 mL/min for a period of 3 days. At predetermined intervals, 
samples were analyzed by an online UV-Vis spectrophotometer at isosbestic point. Results are presented as Mean ± 
SD of n=3 samples. The USP IV method could successfully discriminate between microparticles of Panel B.  
 
Different batches of 85H microparticles were prepared and tested using the developed USP 
IV method to assess if the method could identify batch-to-batch differences between 
microparticles. Table 11 shows the characteristics of the multiple 85H batches. Microparticles 
85H_1, 85H_2 and 85H_3 were three different batches of 85H that were produced. “Batch 0” is 
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the original batch that was produced and is included for comparison. Slight differences in drug 
loading (10-16% w/w) was observed. Two of the three microparticle samples (Batches 1 and 3) 
showed similar dissolution profiles (Figure 19, Table 12), releasing about 80 % MIN over a period 
of 3 days. One batch (Batch 2) showed a different drug release profile, releasing a cumulative of 
60 % MIN over 3 days, similar to the original batch (Batch 0).  
Table 11. Characteristics of 85H Reproducibility Batches 
Microparticle Particle Size (µm) Drug Loading (%) 
Tg (°C) 
Onset Midpoint 
85H_1 40.96±11.24 13.34 52.09 54.88 
85H_2 43.51±12.00 11.07 52.15 54.68 
85H_3 43.25±9.87 10.44 51.56 54.17 




Figure 19. Dissolution Profiles of Multiple Batches of 85H. About 10 mg of microparticles were added to Float-A-
Lyzer® dialysis devices of 50 kDa MWCO. The dialysis devices were inserted in USP IV flow-through cells and 
incubated at 37°C. Dissolution cells were subjected to a continous flow of 0.1% sodium azide in PBS at 10 mL/min 
for a period of 3 days. At predetermined intervals, samples were analyzed by an online UV-Vis spectrophotometer at 
isosbestic point. Results are presented as Mean ± SD of n=3 samples. The microparticles showed lot-to-lot differences, 







Table 12. Statistical Analysis of Dissolution Profiles of Multiple 85H Batches. Numbers in bold denote values 
which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
85H_1 vs. 85H_2 19.84 42.51 N 
85H_2 vs. 85H_3 24.37 41.23 N 
85H_1 vs. 85H_3 3.86 74.92 Y 
85H_1 vs. 
85H_Batch0 
27.67 37.89 N 
85H_2 vs. 
85H_Batch0 
11.25 61.51 Y 
85H_3 vs. 
85H_Batch0 
26.81 37.94 N 
4.3.5  Method Reproducibility 
Arestin® dissolution was performed at three different times by two analysts using the USP 
IV method to check for reproducibility of the method. As seen in Figure 20, all three Arestin® 
runs were found to be f1- f2 similar to each other. The f1 and f2 comparisons of the obtained 
dissolution profiles are listed in Table 13. All values fall within the range, confirming the 
repeatability of the method. 
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Figure 20. Overlay of Dissolution Profiles of Three Arestin® Runs. Two units of Arestin® were added to Float-
A-Lyzer® dialysis devices of 50 kDa MWCO. The dialysis devices were inserted in USP IV flow-through cells and 
incubated at 37°C. Dissolution cells were subjected to a continous flow of 0.1% sodium azide in PBS at 10 mL/min 
for a period of 3 days. At predetermined intervals, samples were analyzed by an online UV-Vis spectrophotometer at 
isosbestic point. Results are presented as Mean ± SD of n=3 samples of 3 individual runs of Arestin®. All three runs 
of Arestin® were similar to each other, indicating that the method is reproducible. 
 
Table 13. Statistical Analysis of Dissolution Profiles of Multiple Runs of Arestin®. Numbers in bold denote 
values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
Run 1 vs. Run 2 3.48 77.05 Y 
Run 2 vs. Run 3 6.96 64.74 Y 
Run 3 vs. Run 1 10.55 56.55 Y 
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4.4 Analysis of Microparticles using the Small Volume Method 
The SVM was evaluated using microparticles of Panel B to assess its discriminatory 
potential and reproducibility. The effect of flow rate on drug release of MIN solution and Arestin® 
was also assessed. The discriminatory ability was assessed by performing dissolution of Panel B 
microparticles (compositional changes). The reproducibility of the method was determined by 
performing the dissolution of Arestin® microparticles multiple times.   
4.4.1  Analysis of MIN by UPLC 
A stability-indicating UPLC assay was developed and qualified for use in-house. The 
method was used for analyzing drug content of microparticles and dissolution samples. Figure 21 
shows a representative chromatogram. The method was linear in the concentration range of 0.125 
– 50 µg/mL (Figure 22). Dissolution samples were collected during the biorelevant test and stored 
at -80°C prior to analysis. The stability of samples (20 and 50 µg/mL) was measured in 20 % 
acetonitrile in sGCF over a period of 7 months. A percent recovery of 97 – 101 % was obtained, 
which suggested that the dissolution samples were stable during the time frame. Stability of the 
samples on tray by measuring % recovery of QC samples (20 µg/mL) over 53 hours. More than 
95 % recovery was obtained over the time frame, suggesting that the samples were stable on tray. 
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Degradant Retention Time (min) Relative Retention Time 
Epimer 1.394 0.425 
Minocycline HCl 3.278 1.000 
Figure 21. Representative Chromatogram of Arestin® Dissolution Sample 
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4.4.2  MIN solution 
Figure 23 shows the dissolution profiles of MIN solution (2 mg/mL) performed using flow 
rates of 0.5 µL/min, 2 µL/min and 10 µL/min. As expected, release of MIN solution was dependent 
on the flow rate used. The time to reach plateau decreased from 4 days for 0.5 µL/min to 22 hours 
for 2 µL/min and 9 hours for 10 µL/min. This result suggests that the release of MIN is dependent 
on the concentration flux created inside the dissolution cells and is not a function of membrane 
permeability.  
 
Figure 23. Effect of Flow Rate on Release of Minocycline Solution from Small Volume Method. Two-hundred 
and fifty microliters of MIN solution (2 mg/mL in sGCF) was added to dialysis enclosures of 50 kDa MWCO. The 
dialysis enclosure was incubated at 37°C and subjected to continous flow of sGCF at 0.5, 2 or 10 µL/min. Samples 
were collected at regular intervals and analyzed for MIN content by a UPLC-based assay. Results are presented as 
Mean ± SD of n=4 samples. Increase in flow rate increases the rate of release of MIN from the dialysis enclosure, 
indicating that the release of MIN depends on the concentration gradient and is not affected by the dialysis membrane. 
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4.4.3  Arestin® 
Arestin showed a cumulative release of about 65 % over 2 weeks (Figure 24) in the 
biorelevant method. A fairly constant release was observed until a period of 5 days, after which 
the release plateaued.  
 
Figure 24. Drug Release from Arestin® Obtained by Small Volume Method. One unit of Arestin® was dispersed 
in 250 µL of sGCF in dialysis enclosures of 50 kDa MWCO. The dialysis enclosure was incubated at 37°C and 
subjected to continous flow of sGCF at 0.5 µL/min. Samples were collected daily and analyzed for MIN content by a 
UPLC-based assay. Results are presented as Mean ± SD of n=4 samples. A fairly constant release is observed during 
the initial 5 days, after which the release plateaus.  
 
In order to assess the effect of flow rate on dissolution of Arestin®, experiments were 
performed at 0.5 and 2 µL/min flow rates. Dissolution profiles of Arestin® at 0.5 and 2 µL/min 
are shown in Figure 24. Because the sampling time points did not match between these runs, the 
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dissolution data was fitted with a polynomial function (Figure 26) to obtain predicted % dissolved 
values from the trendlines. The release profiles were analyzed for similarity (f2) and difference 
(f1) factors. As seen in Table 14, flow rate did not have a significant impact on drug release from 
Arestin®, although an increased dissolution trend was observed with higher flow rate. It has been 
reported that the flow rates in the gingival pocket range from 0.33 – 2.24 µL/min [90]. These 
results indicate that the release of MIN from Arestin® microparticles is independent of the flow 
rates present clinically. However, the dissolution may be affected with further increase (or 
decrease) in flow rates, which was not evaluated in this study.  
 
Figure 25. Drug Release from Arestin® in Small Volume Method at Different Flow Rates. One unit of Arestin® 
was dispersed in 250 µL of sGCF in dialysis enclosures of 50 kDa MWCO. The dialysis enclosure was incubated at 
37°C and subjected to continous flow of sGCF at 0.5 or 2 µL/min. Samples were collected daily and analyzed for 
MIN content by a UPLC-based assay. Results are presented as Mean ± SD of n=4 samples. The release of Arestin® 




Figure 26. Fitting of Polynomial Trendline to Obtained Drug Release Profiles of Arestin®. The dissolution 
profiles of Arestin® obtained using flow rates of 0.5 and 2 µL/min were acquired at different timepoints. Similar 
timepoints are required in order to calculate f1 and f2 values to compare the dissolution profiles. Thus, the profiles 
were fitted onto polynomial curves and % dissolved values at pre-determines timepoints were estimated. These 
estimated values were used to calculate the f1 and f2 values for comparing the two profiles. 
 
Table 14. Statistical Analysis of Drug Release Profiles of Arestin® at 0.5 and 2 µL/min Flow Rate. Numbers 
in bold denote values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
Arestin® at 0.5 µL/min 
vs. Arestin® at 2 µL/min 
13.64 55.40 Y 
4.4.4  Panel B Microparticles (Formulation Changes) 
The small volume dissolution profiles of Panel B microparticles (differing in composition) 
are shown in Figure 27. The rank order of microparticles (85H > 50H > 75L > 50L > 85L) is same 
as that observed with the USP IV method. However, the cumulative amount of MIN released 
within 14 days is less than the MIN amount released over 3 days in the USP IV method. As seen 
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in Figure 27, the small volume dissolution method could effectively discriminate between the 
prepared microparticles that are compositionally different.  
 
Figure 27. Drug Release Profiles of Panel B Microparticles (Formulation Chnages) Obtained Using Small 
Volume Method. Around 10 mg of microparticles were dispersed in 250 µL of sGCF in dialysis enclosures of 50 kDa 
MWCO. The dialysis enclosure was incubated at 37°C and subjected to continous flow of sGCF at 0.5 µL/min. 
Samples were collected daily and analyzed for MIN content by a UPLC-based assay. Results are presented as Mean 
± SD of n=4 samples. The biorelevant method could successfully discriminate between microparticles of Panel B. The 
rank order of release from microparticles is constant between the USP IV and biorelevant methods. 
4.4.5  Method Reproducibility 
Dissolution of Arestin® was performed three times using the SVM to check for 
reproducibility of the method. Two different batches of Arestin® were run at different times. As 
seen in Figure 28, two of the three Arestin® runs were f1- f2 similar to each other and different 
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than the first run (original run). The f1 and f2 comparisons of the obtained dissolution profiles are 
listed in Table 15. These results can indicate differences between Arestin® batches, as the runs 
performed using the same batch (Run #2 and Run #3) are shown to be f1- f2 similar.  
 
Figure 28. Dissolution Profiles of three Arestin® Runs Obtained Using Small Volume Method. One unit of 
Arestin® was dispersed in 250 µL of sGCF in dialysis enclosures of 50 kDa MWCO. The dialysis enclosure was 
incubated at 37°C and subjected to continous flow of sGCF at 0.5 µL/min. Samples were collected daily and analyzed 
for MIN content by a UPLC-based assay. Results are presented as Mean ± SD of n=4 samples of 3 individual runs of 
Arestin® microparticles. Runs #2 and #3 were similar to each other and different to run #1. The differences between 





Table 15. Statistical Analysis of Dissolution Profiles of Multiple Runs of Arestin®. Numbers in bold denote 
values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
Run 1 vs. Run 2 23.91 43.78 N 
Run 2 vs. Run 3 5.85 78.33 Y 
Run 3 vs. Run 1 39.27 40.26 N 
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5.0 Discussion 
There are several methods reported in the literature that can be used to evaluate drug release 
from PLGA microparticles [17, 44-46, 55, 61, 117, 118]. Many of these tests are conducted for 
microparticles that are developed for parenteral administration. For microparticles intended to be 
administered in the periodontal pocket (such as Arestin®), the current USP method utilizes a 
sample-and-separate type approach. This method utilizes agitation forces during incubation and is 
not biorelevant. The discriminatory potential of the method has also not been reported. Given these 
limitations, the current work attempts to address some of the limitations of the currently used 
methods by developing a novel, more biorelevant dissolution method. Further, attempts were made 
to develop a rapid screening method utilizing a compendial-level standardized USP IV apparatus. 
This method can be used during routine quality control analysis. Both the developed methods were 
shown to be discriminatory and reproducible.  
5.1 Selection of Test Conditions for Dissolution Methods 
As discussed previously, there are multiple variables that need to be determined while 
developing a dissolution method. In general, the dissolution media, test temperature, type and rate 
of agitation and method of analysis need to be defined. Type of pump and flow rate are important 
variables that need to be determined for continuous flow methods. For dialysis-based methods, the 
MWCO of the membrane and the volume-ratio of inner chamber to outer chamber are essential.  
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The USP IV method was designed to be a quick method for screening of microparticles. 
An easy-to-prepare and widely used dissolution media was selected for rapid analysis. The USP 
IV method was operated under closed-loop configuration at a flow rate of 10 mL/min. An internal 
volume of 1.8 mL and a reservoir volume of 80 mL was used for the method. The test was carried 
out at a physiological temperature of 37°C. Selection of MWCO of the dialysis membrane was 
based on the molecular size of MIN (~ 494 Da). It is reported that the MWCO of dialysis 
membranes should be around 100 times more than the molecular size [119]. Hence, a Float-A-
Lyzer® device of MWCO of 50,000 Da (50 kDa) was used for the method.  
It has been previously reported that MIN undergoes extensive degradation in PBS [108]. 
About 10 % MIN degrades within an hour at 37°C. PLGA microparticles have been reported to 
release drug in multiple phases. The first “burst release” phase is usually controlled by diffusion. 
The second phase is usually a “lag phase” which is the phase of lower drug release. This phase is 
followed by the third phase of “second burst release” which is controlled by polymer erosion [63]. 
During the “lag” phase, the amount of drug released will be lower than the amount of drug being 
degraded in the release medium. Thus, the apparent MIN concentration in the release medium will 
continuously reduce over 3 days due to degradation instead of remaining constant, posing a 
challenge for development of an online-UV assay. This problem was partially solved by measuring 
drug release at isosbestic point. As seen in Figure 12, MIN displays near constant absorbance in 
the isosbestic region between 276 – 312 nm, where the absorbance of the sample is proportional 
to the total concentration of MIN and its degradants. A wavelength of 292 nm, which lies 
approximately in the middle of this range was selected for online UV analysis. The choice of 
wavelength was confirmed by evaluating drug release from MIN solution in the USP IV method. 
As seen from Figure 14, the drug release from MIN solution plateaus in about 6 hours and remains 
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constant (instead of reducing) over a period of 3 days, justifying the choice of wavelength for 
online-UV analysis. 
For the biorelevant SVM, sGCF was developed and used as the biorelevant release media. 
The sGCF simulates the ionic strength of the major ions present in GCF, pH, and to some extent 
the protein content. The actual protein content of GCF is significantly high and poses challenges 
to simulate in vitro. The test was run at a physiological temperature of 37°C. Arestin® 
microparticles adhere to the gums immediately after insertion [120]. Thus, the use of any type of 
agitation to decrease the presence of unstirred layers surrounding the dialysis tubes is not 
biorelevant and was avoided. A dialysis-based method was selected as it serves a dual purpose. 
First, the dialysis enclosure contains microparticles and separates them from the dissolution media. 
Secondly, they more closely mimic in vivo settings where microparticles are deposited in the 
periodontal pocket and become immobilized, surrounded by a layer of unstirred fluid (GCF) [121]. 
The SVM was run at the biorelevant flow rate of 0.5 µL/min in an open loop configuration, to 
mimic the continuous flow and replenishment of GCF as experienced in vivo.  
A media volume of 250 µL in the inner chamber was utilized in the SVM. Though a volume 
of 250 µL is not biorelevant, it is more practical to use in an in vitro setting. In order to maintain 
an appropriate concentration gradient between the inside and outside of a dialysis membrane, the 
volume outside the dialysis enclosure should be 6-10 times more than the volume inside [44]. 
However, this requirement holds for pure dialysis methods that are not under continuous flow of 
media. In our setting, at any given point of time, the media in the outer chamber is about 3 times 
the media in the inner chamber. However, media is continuously flowing through the dissolution 
cells, replenishing the dissolution media present outside the dialysis membrane. This continuous 
media flow should help in maintaining the concentration gradient. Moreover, since the SVM is a 
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biorelevant method, it is not subject to the requirements of general dialysis-based methods, which 
do not mimic in vivo conditions. Of note, the requirement for sink may be met in the dialysis 
enclosure. However, the rate of media replenishment outside the dialysis membrane affects drug 
diffusion and may impact release from the microparticles. 
In order to quantify the amount of MIN released during the biorelevant dissolution run, a 
stability-indicating UPLC-based assay was utilized. Only the MIN peak, and not the epimer or 
other degradant peaks, was considered to account for the percent drug released. Thus, the SVM is 
a quantitative method that can be utilized to measure the absolute amount of MIN released over 
the test period.  
5.2 Effect of Flow Rate on Drug Release 
The effect of flow rate on release of MIN solution and Arestin® was assessed using the 
SVM. MIN solution (2 mg/mL) was subjected to dissolution using SVA at flow rates of 0.5, 2 and 
10 µL/min. Since MIN solution had drug in dissolved state, the amount of MIN released will 
depend on two factors: a) rate of re-establishment of concentration gradient between the sGCF in 
the inner and outer chambers and b) the diffusibility of MIN across the dialysis membrane. When 
the flow rate is increased, media in the outer chamber is replenished at a faster rate, which increases 
the concentration gradient between the inner and outer chambers. Increased flow rate also reduces 
the layer of unstirred water molecules on the boundary of the dialysis membrane [44]. Thus, higher 
flow rate is expected to increase the rate of drug release, which was observed in case of MIN 
solution (Figure 23). Greater than 90 % MIN solution is released within 24 hours at 2 and 10 
µL/min flow rate, suggesting that the low release observed in the 0.5 µL/min run is due to a low 
 78 
concentration flux and not because of the barrier properties of dialysis membrane. Interestingly, 
when MIN solution was evaluated for drug release at a flow rate of 0.5 µL/min, the release 
approached a plateau at ~ 80 % release (~ 5 days). A complete release was not observed. This can 
be attributed to the degradation of MIN in the dissolution cells and samples as the solutions were 
exposed to 37°C for prolonged periods of time. 
In case of Arestin®, increase in flow rate from 0.5 to 2 µL/min did not significantly 
increase the release of MIN (Figure 25, Table 14). A maximum difference of ~ 10 % in the two 
dissolution profiles was observed at Day 1. This difference was maintained almost constant 
throughout the run. This can be due to the extended release behavior of Arestin® microparticles. 
Arestin® releases ~20 % of MIN within one day under biorelevant conditions. This amounts to 
200 µg of MIN, released in 250 µL of sGCF (inner chamber volume). The final concentration of 
MIN in the inner chamber is 800 µg/mL, which is significantly less than the saturation solubility 
of MIN in sGCF (> 2 mg/mL). Under higher flow rate, MIN is released faster due to faster re-
establishment of concentration gradient between the inner and outer chambers. On the contrary, 
under lower flow rate, the concentration flux will not be re-established that fast, hindering drug 
diffusion from inside the inner chamber to outside. This explains the 10 % difference in MIN 
release observed between 0.5 and 2 µL/min flow rates. Interestingly, the flow rate in the 
periodontal pocket has been reported to be anywhere between 0.33 – 2.28 µL/min [90]. As seen 
from Table 14, the release of MIN from Arestin® microparticles does not vary significantly in this 
clinically relevant range.  
It is worthy to note that flow rate is an important parameter when using a purely continuous-
flow method, where the media comes in direct contact with the test product. In this case, a higher 
flow rate not only determines the concentration gradient but also interaction between media and 
 79 
test sample. Higher flow rate leads to better hydration of the particles [122], and induce shear 
depending on the flow regime (laminar vs. turbulent), resulting in higher drug release. However, 
when the particles are enclosed in a dialysis-sac, flow rate can be expected to have a lesser effect 
on drug release.   
5.3 Assessing the Discriminatory Potential of Developed Methods 
A good dissolution method for quality control analysis of finished drug products should be 
able to discriminate between microparticles that are chemically equivalent but may not have 
similar physical properties. For example, physical properties of microparticles can change due to 
differences in processing parameters such as stir rate and ratio of solvent [123, 124]. To replicate 
these differences, microparticles were fabricated using the same raw materials but by deliberately 
changing the process parameters (stir speed and solvent ratio, see Panel A). The goal of the 
experiment was to assess if the USP IV method, with potential application in routine quality control 
analysis, could identify differences between particles that were chemically equivalent but had 
different physical properties. The prepared microparticles showed differences in particle size, as 
summarized in Tables 8 and 9. The USP IV method was able to differentiate between 
microparticles of Panel A (Figure 16, 17, Table 10). Since differences in manufacturing during 
production usually arise due to deviations in process parameters, the ability of a dissolution method 
to identify such dissimilarities become crucial.  
In order to assess bioequivalence of generic products, the FDA requires generic products 
to be Q1/Q2 similar to the RLD. Accordingly, a dissolution method intended for bioequivalence 
testing should be able to discriminate between microparticles that are Q1/Q2 different than the 
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RLD. Thus, a panel of microparticles that were compositionally different to Arestin® were 
fabricated. These microparticles had different LA:GA ratios, Mw and drug loading than Arestin® 
(see Panel B). As seen in Figures 18 and 27, both the developed methods could effectively 
discriminate between microparticles of Panel B.  
In general, the USP IV method operates under conditions that can be considered as 
‘accelerated’ compared to the biorelevant method. The method utilizes a very high flow rate of 10 
mL/min, internal volume of 1.8 mL and media reservoir of 80 mL. Although the method utilizes 
physiological temperature of 37°C, the larger amount of media in the dialysis tube, nature of media 
and high flow rate can accelerate drug release from microparticles. As reported earlier, increased 
flow rate causes a greater diffusion flux, resulting in higher diffusion of the drug from inside the 
dialysis bag to outside [56]. Zolnik, B. S. and colleagues reported that increasing flow rate 
increases drug release from low Mw PLGA microparticles, with diffusion-controlled release 
kinetics. However, flow rate did not have any effect on drug release from high Mw PLGA 
microparticles, which were believed to show erosion-controlled release kinetics [56]. The 
differences in media flow rate between USP IV method and SVM are significantly higher than 
reported in the literature, which in combination with the dialysis enclosure volume could impact 
drug release. The initial burst phase, which is usually diffusion-controlled, is the region that defines 
the discriminatory potential of a dissolution method. Thus, a slower burst phase, as observed in 
the SVM, can potentially enable the biorelevant dissolution method to have a better discriminatory 
potential than the USP IV method.  
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5.4 Dependence of Rate of Release on Microparticle Properties 
In general, it was observed that drug release from microparticles composed of a particular 
LA:GA ratio depended on the Mw of PLGA. Microparticles composed of higher Mw PLGA 
released higher amount of MIN than those composed of lower Mw PLGA (Figures 18, 27). As 
previously mentioned, usually Mw and drug release have an inverse relationship. The opposite 
effect seen in our studies can be attributed to the following two reasons. First, MIN is a tetracycline 
analogue with multiple sites of ionization. MIN has four pKas, as depicted in Figure 29A [99, 
125]. During dissolution, MIN is already positively charged, which can interact with the acid end 
groups of PLGA. The effect of ionic interaction between positively charged proteins and uncapped 
(acid-end) PLGAs on drug release has already been studied by Balmert, S. C. and coworkers [126]. 
The group showed that positively charged peptides show lesser drug release than neutral peptides. 
Moreover, drug release of positively charged peptides from higher Mw PLGA was higher than 
that from lower Mw PLGA. This effect is similar to what was observed in our studies. 
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Figure 29. (A) Sites of Interaction between MIN and PLGA and (B) Flow Chart Explaining the Relation 
Between Mw and Drug Release 
Another reason for the positive correlation of drug release and Mw can be attributed to 
faster decrease in intraparticular pH of lower Mw PLGA microparticles. Balmert, S. C. and group 
reported that the intraparticular pH decreases much faster in case of lower Mw PLGA as compared 
to higher Mw PLGA [126]. The group found that the intraparticular pH was below 4.5 for lower 
Mw PLGA (7 and 15 kDa) within 1 hour of incubation in PBS solution. The pH reduced to 3.3 
within 3 days and as low as 2.2 within 12 days. In contrast, the pH of higher Mw PLGA (43 kDa), 
was 6 after 1 hour of incubation in PBS and reduced gradually to 3.2 over 21 days. Thus, the 
interaction of MIN in microparticles composed of lower Mw PLGA would be stronger than that 
in higher Mw PLGA, reducing the drug release from microparticles fabricated with lower Mw 
PLGA (Figure 29B).  
It should be noted that, drug release during the initial timepoints can be attributed to un-
encapsulated drug present at the surface of the microparticles. During this initial phase, drug 
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release will not be dependent on the fraction of MIN that is bound to PLGA within the 
microparticles. However, once the un-encapsulated drug is released from the microparticles, the 
effect of interaction of MIN with PLGA becomes more prominent. During this stage, release of 
MIN is diffusion controlled. Thus, the higher amount of unbound MIN present in microparticles 
composed of high Mw PLGA would be released faster (and to a greater extent) than from 
microparticles composed of low Mw PLGA. However, drug-polymer interaction may not 
significantly affect drug release during the later stages, where drug release is controlled by polymer 
erosion. Polymer erosion can explain the almost zero-order release of MIN from 50L 
microparticles (Figure 27). Microparticles 50L are composed of low Mw PLGA (50:50 LA:GA) 
and can be expected to have the fastest rate of polymer erosion [72]. 
Other reasons that may affect the release of MIN from microparticles include the internal 
structure of microparticles, porosity, particle size, drug loading and distribution of drug within the 
microparticles. There may be differences in the amount of free drug vs. bound drug inside the 
microparticle, which may affect drug release but has not been accounted for in this work. It is 
important to note that although attempts have been made to explain the order of drug release from 
different microparticles using the designed methods, the goal of the study was to assess the 
discriminatory potential of the method and not study the effects of microparticle properties on 
release behavior of MIN. 
5.5 Assessing the Reproducibility of the Methods 
It is important for any dissolution method to produce reproducible and reliable results. The 
reproducibility of the methods was assessed by comparing multiple runs of Arestin®. The same 
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batch of Arestin® microparticles were used to assess repeatability of the USP IV method. Using 
the same batch assured that the results were not affected by differences in microparticles that may 
exist between different batches. One of the runs was performed by a second analyst to account for 
variations between analysts.  As seen in Figure 20, the three Arestin® dissolution profiles were 
very similar. Statistical analysis of the dissolution profiles (Table 13) confirm that the dissolution 
profiles are f1-f2 similar to each other.  
Once the reproducibility of the USP IV method was determined, different batches of 85H 
microparticles were prepared and tested for drug release using the method. As seen in Figure 19 
and Table 12, only two of the four batches produced showed f1-f2 similarity in the dissolution 
profiles. Differences in dissolution profiles may be attributed to the following three factors: 
variation in the method, batch-to-batch differences between microparticles and differences in 
sampling. Since the reproducibility of the USP IV method has already been established by 
comparing multiple runs of Arestin®, differences in dissolution profiles of 85H reproducibility 
batches can be attributed to batch-to-batch differences or differences in sampling. It has been 
previously reported that the effect of lot-to-lot differences during dissolution method development 
can be eliminated by normalizing release profiles to the total amount of drug released [127]. Thus, 
the obtained drug release profiles of 85H repeatability batches were normalized to the total amount 
of drug released over 3 days to account for batch-to-batch differences between microparticles. 
Figure 30 shows the dissolution profiles of 85H repeatability batches upon normalization. When 
the dissolution profiles were normalized, the profiles were found to be f1/f2 similar (Table 16).  
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Figure 30. Normalized Dissolution Profiles of 85H Repeatability Batches.  Drug release profiles of various batches 
of 85H microparticles were normalized to the total amount release in order to eliminate batch-to-batch differences 
between the microparticles. After normalization, the release profiles were found to be f1/f2 similar to each other, 
indicating that the differences between microparticles are not indicative of method variability. 
 
Table 16. Statistical Analysis of Normalized Dissolution Profiles of Multiple 85H Batches. Numbers in bold 
denote values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
85H_1 vs. 85H_2 4.79 65.28 Y 
85H_2 vs. 85H_3 8.87 51.86 Y 
85H_1 vs. 85H_3 4.81 65.75 Y 
85H_1 vs. 
85H_Batch0 
5.18 66.99 Y 
85H_2 vs. 
85H_Batch0 




9.25 55.71 Y 
 
The differences in the total amount of MIN released from 85H microparticles can stem 
from differences in the internal structure of microparticles, the distribution of MIN within the 
microparticles, porosity and overall size differences. Moreover, there can be differences in the 
amount of bound vs. free MIN inside the particles. Free drug diffuses faster than the bound drug, 
increasing the total amount of MIN released. Thus, to completely understand the drug release 
behavior of the produced microparticles, a thorough microparticle characterization will have to be 
performed, which is beyond the scope of this work. Moreover, the clinical relevance of these 
differences in drug release is not known and will have to be studied to assess the applicability of 
the method. 
For the SVM, two batches of Arestin® were used due to unavailability of the same lot. 
Runs 2 and 3 were similar to each other and different from the first run (Figure 28 and Table 15). 
The differences in release profiles could be attributed to differences between the lots of Arestin®. 
Runs 2 and 3 were carried out using the same lot of Arestin®, while run 1 was carried out on a 
different lot. To account for batch-to-batch differences between Arestin® runs, the release profiles 
were normalized to the total amount of drug released. Because the sampling time points did not 
match between the runs, the dissolution data was fitted with a polynomial function to obtain 
predicted % dissolved values from the trendlines (data not shown). Similarity (f2) and difference 
(f1) factors were calculated using these values. After normalization, the dissolution profiles of all 
Arestin® runs were f1-f2 similar, as seen in Figure 31 and Table 17. This suggests that the 
individual runs differ in absolute amount of MIN released but not in the way in which they release 
MIN, which may reflect differences between individual lots of Arestin®. Although the different 
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batches of Arestin® show different release profiles in SVM, they may have passed the dissolution 
test as per USP criteria for periodontal systems containing MIN (Table 3), where a minimum of 
12.6 % of MIN should be released at the end of 3 days. This argument seems plausible as the lots 
release at least 32 % MIN over 3 days even in the SVM, under extremely small volumes and flow 
rates. However, in order to be confident about repeatability of the method, another SVM run of 
Arestin® using the same lot will have to be performed. 
 
Figure 31. Normalized Dissolution Profiles of the Three Arestin® Small Volume Runs. Drug release profiles of 
three individual Arestin® runs carried out using the biorelevant method were normalized to the total amount released. 
Normalization was done in order to eliminate batch-to-batch differences between the microparticles. After 
normalization, the release profiles were found to be f1/f2 similar to each other, indicating that the differences between 
microparticles stem from differences between lots of Arestin® and are not indicative of method variability. 
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Table 17. Statistical Analysis of Normalized Dissolution Profiles of Multiple Arestin® Batches. Numbers in 
bold denote values which are within limits (f1 < 15, f2 > 50). 
 Difference Factor (f1) Similarity Factor (f2) Similar? 
Run 1 vs. Run 2 1.36 89.47 Y 
Run 2 vs. Run 3 2.17 79.32 Y 
Run 3 vs. Run 1 3.44 72.67 Y 
5.6 Impact of the Work and Potential Applications 
Two reliable, discriminatory and reproducible dissolution methods were developed that 
have distinct advantages over each other. The USP IV method utilizes a compendial dissolution 
apparatus to test drug release from PLGA microparticles under real-time conditions (37°C). A 
complete release from Arestin® is achieved within 3 days without employing elevated 
temperatures. The method is carried out using an online UV-Vis spectrophotometer, which avoids 
the need to analyze the samples after completion of the run. Data is obtained reasonably fast, 
reducing the number of person-hours required to carry out the test. Using the USP IV apparatus 
comes with the inherent advantages of lab-to-lab uniformity, reliability and easy transferability. 
The method is simple and can be employed during drug development for determining ideal process 
and formulation parameters. The method can also be used for routine quality control analysis to 
check for batch-to-batch variability.  
The SVM is a novel and more sensitive dissolution method. It provides the most practical 
representation of the in vivo environment for periodontal systems. Currently, there are more than 
15 PLGA-based FDA approved products in the market. However, no generic PLGA-based product 
has received FDA approval as yet. The SVM can potentially be used as an in vitro alternative to 
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test generic versions of Arestin® for bioequivalence. It can also be used in lieu of clinical testing 
during scale-up of batches and to prove bioequivalence during post-approval changes. Further, 
given the similarity of test conditions to in vivo environment, the antimicrobial activity of the 
samples collected can be tested and the results can serve as proof of efficacy of the product over a 
period of 14 days (or longer, unpublished results). SVM can also be used to validate the 
manufacturing processes on an annual basis during large-scale production of periodontal 
microparticles. The use of SVM can be extended to test other dosage forms intended for localized 
delivery in the periodontal pocket. 
In fact, the pumps and flow rates can be adjusted to simulate fluid-flow rates present in 
different parts of the body. The dissolution cells can be agitated to simulate the blinking of eyelids 
and turnover rate of lacrimal fluid. Thus, the use of the SVA shows promise to test drug release 
from other micro- and nanoparticulate systems, powders, solutions, suspensions, sprays and other 
formulations intended to be administered in small cavities such as the nasal, otic and ocular 
pockets. The small volume cell can also be modified to test drug release from vaginal products. 
For instance, a miniaturized USP I-type basket can be used as the sample holder. Clips can be 
utilized to secure the dosage form in the basket. The mesh size of the basket will have to be 
optimized in order to separate undissolved material from the dissolution media while preventing 
problems of back-pressure and clogging. The inner chamber can be designed to have a volume of 
1 mL and flow rate of 4.2 µL/min to simulate conditions present in the vagina [41, 128]. Glass 
beads and agitation can be introduced to simulate mechanical forces normally encountered. Flow 
rate and agitation can be modified during the run to simulate changes relating to the menstrual 
cycle. 
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Overall, the SVA is a novel biorelevant apparatus that has potential for adaptation towards 
a variety of applications. The SVM described here is the first application and proof-of-concept of 
the apparatus. The current work focusses on assessing the method’s discriminatory ability and 
reproducibility in an effort to justify the SVA’s use for drug release testing of MIN-loaded PLGA 
microparticles intended for application in the periodontal pocket.  
5.7 Limitations of the Developed Methods 
Both the developed methods were reproducible and exhibited a good discriminatory 
potential. Despite this, the developed methods possess certain limitations. Some advantages of the 
USP IV method include that it quick, it is based on a compendial system and it has an on-line UV 
system that reports the results without having the need to collect and analyze samples separately. 
However, since MIN is highly sensitive to hydrolytic degradation, the UV analysis needs to be 
carried out at isosbestic point. Because the online-UV system measures the total amount (drug + 
degradants) of MIN released, it does not give the absolute amount of MIN released. Moreover, the 
method may overestimate the amount of MIN released by up to 20 % for MIN solution. Thus, the 
drug release profiles may need to be normalized with respect to MIN solution during practical 
applications. A simple way to improve the sensitivity of the method is to collect samples at 
predetermined timepoints and analyze them to give the drug release profile. Although more 
cumbersome, this technique may be more reliable and quantitative, especially for the first 24 hours. 
However, it should be noted that MIN may degrade into several degradants that do not appear on 
the chromatogram, making quantitation challenging. 
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The SVM is a miniaturized version of the USP IV method with modifications that make 
the method more biorelevant. The method simulates more closely the flow rates, media and 
volumes that are experienced by periodontal microparticles in vivo. Since the length of dissolution 
study is 2 weeks, its application during formulation development may be met with practical 
limitations of length timelines. However, SVM may be more applicable to determine 
bioequivalence of generic and brand name products. Another major limitation of the SVM is that 
it requires special dissolution cells which are not yet commercially available. The method may 
also show extremely small differences between microparticles, which may not be clinically 
relevant. Thus, more work needs to be done to determine the criteria for acceptance of products 
tested using the SVM.  
 92 
6.0 Conclusion and Future Directions 
Two reliable and reproducible dissolution methods were developed which could 
successfully discriminate between the prepared comparators. The USP IV method is a rapid 
dissolution test that can be used in drug development for determining optimum process and 
formulation parameters. It is semi-quantitative in nature as it provides the overall percentage of 
MIN released but cannot be used to quantify the absolute amount of MIN released. The method is 
reproducible and can be reliably used during product development for rapid screening of prototype 
drug formulations. The SVM has potential to exhibit a better discriminatory power than the USP 
IV method, as the SVM extends the ‘burst phase’ drug release from microparticles to ~ 5 days. 
The SVM can be used to calculate the amount of MIN released over time and is thus quantitative 
in nature. With certain modifications, the SVA can be used to test other dosage forms intended to 
be delivered in extremely small cavities, such as the nasal, otic and ocular sacs. The SVM can also 
be potentially used to test the bioequivalence of different MIN-loaded PLGA microparticles used 
in periodontitis. 
More studies comparing the in vitro release data to in vivo dissolution profiles will need to 
be performed in order to determine the clinical relevance of the SVM. The acceptance criteria for 
products tested with both the methods needs to be established. Future work will also focus on 
testing microparticles of Panel A (process changes) using the SVM to demonstrate that the method 
can discriminate between them. The main goal of future experiments would be to compare the in 
vitro and in vivo release profiles in order to develop and validate a robust IVIVC. 
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Appendix A : Abbreviations Used 
  
AUC : Area under the curve 
BA : Bioavailability 
BCS : Biopharmaceuticals classification system 
BE : Bioequivalent 
CFR : Code of Federal Regulations 
Cmax : Maximum plasma concentration 
DCM : Dichloromethane  
DSC : Differential scanning calorimetry 
ER : Extended-release 
f1 : Difference factor 
f2 : Similarity factor 
FDA : Food and Drug Administration 
GCF : Gingival crevicular fluid 
GI : Gastro-intestinal 
HPLC : High performance liquid chromatography 
IUPAC : International Union of Pure and Applied Chemistry 
IR : Immediate-release 
IVIVC : In vitro-in vivo correlation 
LA:GA : Lactic acid-to-glycolic acid ratio 
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MIN : Minocycline hydrochloride 
MR : Modified-release 
MWCO : Molecular weight cut-off 
NF : National Formulary 
NLT : Not less than 
PBPK : Physiologically-based pharmacokinetic model 
PDLA : Poly(D-lactic acid) 
PGA : Poly(glycolic acid) 
PLA : Poly(lactic acid) 
PLGA : Poly(lactic-co-glycolic acid) 
PLLA : Poly(L-lactic acid) 
QbD : Quality by design 
SEM : Scanning electron microscopy 
sGCF : Simulated gingival crevicular fluid 
SOP : Standard operating procedure 
SRP : Scaling and root planing 
SVA : Small volume apparatus 
SVM : Small volume method 
Tg : Glass transition temperature 
UPLC : Ultra-high performance liquid chromatography 
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